Modified high molecular weight glutenin subunits and uses thereof

JP2023550979A5Inactive Publication Date: 2024-12-03UKKO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532360
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-07-14
Filing Date
2021-11-24
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for additional dietary treatments for subjects suffering from celiac disease that are both inexpensive and accessible, as strict gluten-free diets are difficult to maintain and often result in inadvertent gluten exposure, leading to persistent intestinal abnormalities and increased risk of complications.

Method used

Development of de-epitoped high molecular weight (HMW) glutenin proteins with specific mutations at positions 1 and 9 of the repeating antigenic units, reducing their immunogenicity and allergenicity by altering CD-associated T cell epitopes, thereby minimizing immune response.

Benefits of technology

The modified HMW glutenin proteins exhibit reduced binding to HLA-DQ2.5 and HLA-DQ8, leading to decreased activation of T cells and IgE binding, making them suitable for individuals with celiac disease, allowing for safer dietary inclusion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Depitopamed high molecular weight (HMW) glutenins are provided, as are methods for producing them and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The ASCII copy, created on November 15, 2021, is named P-608944-PC_SL.txt and is 334,880 bytes in size.

[0002] The present disclosure relates generally to methods for de-epitoping high molecular weight glutenin (HMW glutenin) and its use to manage gluten sensitivity, for example, in subjects suffering from celiac disease. [Background technology]

[0003] Celiac disease (CD) is an acquired chronic immune disorder that occurs in susceptible individuals, most of whom have the HLA genotype DQ2 or DQ8, while a minority of subjects have neither DQ2 nor DQ8, primarily the genotype DQ7.5. The disorder is associated with the environmental factor gluten, a group of seed storage proteins in wheat and related cereals such as rye and barley. HMW glutenin is one of these seed storage proteins. The prevalence of CD in Europe and the United States is estimated to be approximately 1-2% of the population. CD has a wide range of clinical manifestations, including latent or asymptomatic celiac disease, disease with only mild gastrointestinal disturbances, chronic gastrointestinal symptoms, malabsorption, and / or weight loss. CD is often diagnosed in patients with isolated iron deficiency anemia.

[0004] Some CD4-associated T cell epitopes from wheat, barley, and rye are known in the art, see, e.g., Shewry PR, Tatham AS. Improving wheat to remove coeliac epitopes but retain functionality. J Cereal Sci. 2016;67:12-21.

[0005] Ingestion of gluten-containing grains can also induce extraintestinal manifestations such as osteoporosis, peripheral and central nervous system complications, mild or severe liver disease, infertility problems, and a classic example is the gluten-induced skin disease, dermatitis herpetiformis.

[0006] For patients with CD, strict adherence to lifelong complete gluten elimination is required to avoid substantially increased risk of developing further complications, such as bone disorders, infertility, and cancer. Mortality rates in patients with CD exceed those of the general population; however, a gluten-free diet tends to reduce mortality after 1 to 5 years.

[0007] However, adhering to a completely gluten-free diet is extremely difficult. Even highly motivated patients who maintain a strict diet are affected due to inadvertent or background exposure to gluten. As many as 80% of CD patients who claim to be in clinical remission and adhering to a gluten-free diet have persistent abnormalities in small-bowel biopsy specimens. Inadvertent exposure to gluten has been identified as the leading cause of unresponsive CD among clinically diagnosed patients presumed to be on a gluten-free diet.

[0008] In summary, there is an urgent need for additional dietary interventions for subjects suffering from CD that are both inexpensive and accessible. Summary of the Invention

[0009] In one aspect, disclosed herein is a de-epitopeed high molecular weight (HMW) glutenin protein comprising a first mutation at position 1 and a second mutation at position 9 of a repeating antigenic unit, wherein the amino acid sequence of the unmutated repeating antigenic unit is set forth in any of SEQ ID NOs: 1-33, 35, or 71-99. In a related aspect, the amino acid sequence of the non-de-epitopeed HMW glutenin is set forth in any of SEQ ID NOs: 43, 44, 45, 46, 47, 48, 152, 153, or 154, or an amino acid sequence having at least 50% identity to the sequence set forth in any of SEQ ID NOs: 43, 44, 45, 46, 47, 48, 152, 153, or 154.

[0010] In a further related aspect, the first mutation, or the second mutation, or both, comprises a substitution mutation. In another further related aspect, the first mutation, or the second mutation, or both, comprises a deletion mutation. In yet another related aspect, the mutation comprises a substitution mutation that replaces the amino acid residue at position 9 of the repeating antigenic unit with a positively charged amino acid or a small amino acid; or glutamic acid; or a combination thereof if two or more repeating antigenic units are mutated. In one particular aspect, the positively charged amino acid is arginine or histidine; or the small amino acid is serine or threonine; or a combination thereof if two or more repeating antigenic units are mutated.

[0011] In another further related aspect, the mutation at position 1 of the repeating antigenic unit comprises a substitution mutation replacing the amino acid residue at position 1 of the repeating antigenic unit with histidine, proline, serine, alanine, lysine, or glutamic acid.

[0012] In certain related aspects, the substitution at position 1 of the antigenic unit is a substitution with histidine and the substitution at position 9 of the antigenic unit is a substitution with histidine; the substitution at position 1 of the antigenic unit is a substitution with proline and the substitution at position 9 of the antigenic unit is a substitution with arginine; the substitution at position 1 of the antigenic unit is a substitution with alanine and the substitution at position 9 of the antigenic unit is a substitution with arginine; the substitution at position 1 of the antigenic unit is a substitution with serine and the substitution at position 9 of the antigenic unit is a substitution with threonine; the substitution at position 1 of the antigenic unit is a substitution with glutamic acid. and the substitution at position 9 of the antigenic unit is a replacement with glutamic acid; the substitution at position 1 of the antigenic unit is a replacement with proline and the substitution at position 9 of the antigenic unit is a replacement with threonine; the substitution at position 1 of the antigenic unit is a replacement with glutamic acid and the substitution at position 9 of the antigenic unit is a replacement with lysine or arginine; or the substitution at position 1 of the antigenic unit is a replacement with glutamic acid or lysine and the substitution at position 9 of the antigenic unit is a replacement with histidine; or any combination thereof if two or more repeating antigenic units are mutated.

[0013] In a related aspect, disclosed herein is a de-epitope-modified HMW glutenin protein comprising at least two additional substitution mutations at either position 3, 4, or 7 of the repeating antigenic unit. In a further related aspect, the substitution at position 3 is a polar amino acid or a positively charged amino acid; the substitution at position 4 is a negatively charged amino acid or glycine; and the substitution at position 7 is glycine; or any combination thereof when two or more repeating antigenic units are mutated.

[0014] In a related aspect, disclosed herein is a de-epitope HMW glutenin protein comprising at least two additional substitution mutations at either position 3, 5, or 8 of the antigenic unit. In a further related aspect, the substitution at position 3 is a polar or positively charged amino acid; the substitution at position 5 is a hydrophobic amino acid; and the substitution at position 8 is a small or aliphatic amino acid; or any combination thereof when two or more repeating antigenic units are mutated. In another further related aspect, the substitution at position 5 is leucine and the substitution at position 3 is arginine.

[0015] In a related aspect, disclosed herein is a de-epitope HMW glutenin protein, wherein the number of mutated repeating antigenic units comprises at least 5-10 repeating antigenic units, and the mutations within each repeating antigenic unit can be the same or different. In a further related aspect, the first mutation, the second mutation, or both comprise a deletion. In one particular aspect, the deletion comprises deletion of all amino acids at positions 1 through 9 of the repeating antigenic unit.

[0016] In a related aspect, disclosed herein is a depitope-modified HMW glutenin protein comprising an amino acid sequence set forth in any of SEQ ID NOs: 52, 102-107, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, 155-168, or 170-172.

[0017] In another aspect, disclosed herein is an isolated polynucleotide encoding any of the de-epitope-modified HMW glutenin proteins described throughout. In another aspect, disclosed herein is an expression vector comprising an isolated polynucleotide encoding a de-epitope-modified HMW glutenin protein operably linked to a transcriptional regulatory sequence to allow expression of the de-epitope-modified HMW glutenin in a cell.

[0018] In another aspect, disclosed herein is a method for producing a depitopied HMW glutenin, the method comprising culturing a cell comprising the expression vector of claim 18 under conditions that allow expression of the depitopied HMW glutenin in the cell; expressing the depitopied HMW glutenin; and recovering the expressed depitopied HMW glutenin. In a related aspect, disclosed herein is a cell comprising any of the depitopied HMW glutenin proteins described herein.

[0019] In another aspect, disclosed herein is a method for de-epitopling a high molecular weight glutenin protein, comprising mutating the amino acid residues at positions 1 and 9 of at least one repeating antigenic unit of glutenin, wherein the repeating antigenic unit has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-33, 35, or 71-99, thereby producing a de-epitopeed high molecular weight glutenin. In a related aspect, the mutation is performed in at least 5-10 of the repeating antigenic units. In a further related aspect, the mutation comprises substitution of at least two amino acid residues or deletion of amino acid residues. In another further related aspect, the mutation comprises substitution of an amino acid at position 9 of the repeating antigenic unit, wherein the substitution comprises replacement with a positively charged amino acid, a small amino acid, or glutamic acid, or a combination thereof when two or more repeating antigenic units are mutated. In certain aspects, the positively charged amino acid is arginine, histidine, or lysine; and the small amino acid is serine or threonine. In a further aspect, when the mutation comprises a substitution, the substitution at position 9 of the antigenic unit is with arginine, histidine, lysine, threonine, or glutamic acid, or a combination thereof if two or more repeating antigenic units are mutated. In another further aspect, when the mutation comprises a substitution, the substitution at position 1 of the antigenic unit is with histidine, proline, serine, alanine, lysine, or glutamic acid, or a combination thereof if two or more repeating antigenic units are mutated.In related aspects, the substitution at position 1 of the antigenic unit is a substitution with histidine, and the substitution at position 9 of the antigenic unit is a substitution with histidine; the substitution at position 1 of the antigenic unit is a substitution with proline, and the substitution at position 9 of the antigenic unit is a substitution with arginine; the substitution at position 1 of the antigenic unit is a substitution with alanine, and the substitution at position 9 of the antigenic unit is a substitution with arginine; the substitution at position 1 of the antigenic unit is a substitution with serine, and the substitution at position 9 of the antigenic unit is a substitution with threonine; and the substitution at position 1 of the antigenic unit is a substitution with glutamic acid. and the substitution at position 9 of the antigenic unit is a replacement with glutamic acid; the substitution at position 1 of the antigenic unit is a replacement with proline and the substitution at position 9 of the antigenic unit is a replacement with threonine; the substitution at position 1 of the antigenic unit is a replacement with glutamic acid and the substitution at position 9 of the antigenic unit is a replacement with lysine or arginine; or the substitution at position 1 of the antigenic unit is a replacement with glutamic acid or lysine and the substitution at position 9 of the antigenic unit is a replacement with histidine; or any combination thereof if two or more repeating antigenic units are mutated.

[0020] In a related aspect, disclosed herein is a method for de-epitopizing HMW glutenin, further comprising mutating at least two amino acids at positions 3, 4, or 7 of the repeating antigenic unit. In a related aspect, the mutation comprises a substitution of an amino acid residue or a deletion of an amino acid residue. In some aspects, when the mutation is a substitution, the substitution at position 3 is a replacement of the amino acid with a polar amino acid or a positive amino acid; or the substitution at position 4 is a replacement of the amino acid with a negatively charged amino acid or glycine; or the substitution at position 7 is a replacement of the amino acid with glycine; or any combination thereof when two or more repeating antigenic units are mutated.

[0021] In a related aspect, disclosed herein is a method for de-epitopizing HMW glutenin, further comprising mutating at least two amino acids at positions 3, 5, or 8 of the repeating antigenic unit. In a related aspect, when the mutation is a substitution, the substitution at position 3 replaces the amino acid with a polar amino acid or a positively charged amino acid; or the substitution at position 5 replaces the amino acid with a hydrophobic amino acid; or the substitution at position 8 replaces the amino acid with a small amino acid or an aliphatic amino acid; or any combination thereof if two or more repeating antigenic units are mutated. In a further related aspect, the substitution at position 5 replaces the amino acid with leucine, and the substitution at position 3 replaces the amino acid with arginine.

[0022] In a related aspect, disclosed herein is a method of depitopizing HMW glutenin comprising a mutation, wherein the mutation comprises a deletion, and the deletion comprises deleting amino acids 1-9 of a repeating antigenic unit.

[0023] In another related aspect, disclosed herein is a method of de-epitopling an HMW glutenin protein, wherein the de-epitopled HMW glutenin comprises an amino acid sequence set forth in any of SEQ ID NOs: 52, 102-107, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, 155-168, or 170-172.

[0024] In a related aspect, a method for de-epitopizing HMW glutenin includes analyzing the binding affinity of the de-epitopized high molecular weight glutenin for HLA-DQ2.5, HLA-DQ8, HLA-DQ2.2, and HLA-DQ7.5; if the de-epitopized HMW glutenin contains a lower affinity for T cells from a celiac patient compared to the binding affinity of a corresponding unmutated high molecular weight glutenin for T cells from a celiac patient; or if the de-epitopized high molecular weight ... identifying the de-epitope-modified high molecular weight glutenin as having reduced immunogenicity if the de-epitope-modified high molecular weight glutenin activates T cells from a celiac patient to a lesser extent than a corresponding unmutated high molecular weight glutenin activates T cells from the celiac patient; or a combination thereof; or identifying the de-epitope-modified high molecular weight glutenin as not having reduced immunogenicity if the modified antigenic unit of the de-epitope-modified HMW glutenin binds to MHC II class DQ2, DQ2.2, DQ2.5, DQ7.5 or DQ8 with an IC50 of less than 30 μM.

[0025] In a related aspect, a method of de-epitopizing HMW glutenin further comprises analyzing the binding affinity of the de-epitopized high molecular weight glutenin for IgE binding; identifying the de-epitopized high molecular weight glutenin with reduced IgE binding; and assaying the identified de-epitopized high molecular weight glutenin with reduced IgE binding for basophil degranulation, wherein a reduced response compared to the response of wheat extract correlates with the de-epitopized high molecular weight glutenin protein having reduced allergenicity.

[0026] In one aspect, disclosed herein is a flour comprising any of the depitopied HMW glutenin proteins described herein. In another aspect, disclosed herein is a dough comprising flour comprising any of the depitopied HMW glutenin proteins described herein.

[0027] In another aspect, disclosed herein is a modified wheat that expresses any of the depitopied HMW glutenins described herein.

[0028] In another aspect, disclosed herein is a modified corn plant that expresses any of the depitopied HMW glutenins described herein.

[0029] In another aspect, disclosed herein is a flour derived from a wheat or corn plant that comprises depitopied HMW glutenin.

[0030] The subject matter regarded as de-epitope-modified high molecular weight (HMW) glutenin, its method of manufacture, and its uses is particularly pointed out and distinctly claimed in the concluding portion of this specification. However, the de-epitope-modified high molecular weight (HMW) glutenin, its method of manufacture, and its uses, together with its objects, features, and advantages, both as to organization and method of operation, may best be understood by reference to the following detailed description when read in conjunction with the accompanying drawings. [Brief explanation of the drawings]

[0031] [Figure 1A] FIG. 1 depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitopied HMW glutenin polypeptide as set forth in SEQ ID NO: 43. [Figure 1B] FIG. 1 depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitopied HMW glutenin polypeptide as set forth in SEQ ID NO:44. [Figure 1C] FIG. 1 depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitope-modified HMW glutenin polypeptide as set forth in SEQ ID NO: 45. [Figure 1D] FIG. 1 depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitope-modified HMW glutenin polypeptide as set forth in SEQ ID NO: 46. [Figure 1E]FIG. 1 depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitope-modified HMW glutenin polypeptide as set forth in SEQ ID NO: 47. [Figure 1F] FIG. 1 depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitope-modified HMW glutenin polypeptide as set forth in SEQ ID NO: 48. [Figure 1G] FIG. 1 depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitopied HMW glutenin polypeptide as set forth in SEQ ID NO: 152. [Figure 1H] FIG. 1 depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitopied HMW glutenin polypeptide as set forth in SEQ ID NO: 153. [Figure 1I]

[0023] Figure 1A depicts the amino acid sequence of a representative embodiment of a wild-type, non-depitopeed HMW glutenin polypeptide set forth in SEQ ID NO: 154. The antigenic units in Figures 1A-1F are shown in bold. The boxed antigenic unit is the HMW glutenin epitope described in the literature, set forth as SEQ ID NO: 1. The italicized amino acids at positions 1 and 9 are known to occasionally undergo deamidation when tissue transglutaminase converts them to glutamic acid in the small intestine. In certain embodiments, mutations to the repeat antigenic unit include mutations at positions 1 and 9, which may include a glutamine (Q) to glutamic acid (E) conversion. Underlining indicates residues that differ from the HMW glutenin epitope described in the literature, set forth in SEQ ID NO: 1.

[0032] [Figure 2]

[0023] Figure 1 depicts embodiments of 13-mer peptides containing mutations within the repeating antigenic unit. Bold indicates mutant amino acid residues. Underlining indicates positions 1 and 9 of the antigenic unit (epitope core). Peptides identified as SEQ ID NOs: 37 and 39 bind to DQ7.5 (data not shown).

[0033] [Figure 3] FIG. 1 shows that modifications to HMW-GS immunogenic peptides (the modified peptides are SEQ ID NOs: 51 and 53) result in abolishment of T cell activation.

[0034] [Figure 4] FIG. 1 shows that modifications to HMW-GS immunogenic peptides (the modified peptides are SEQ ID NOs: 52, 54, and 55) result in abolishment of T cell activation.

[0035] [Figure 5] FIG. 1 shows that modifications to the HMW-GS immunogenic peptide (the modified peptide is SEQ ID NO: 56) result in abolishment of T cell activation.

[0036] [Figure 6] FIG. 1 shows that modifications to the HMW-GS immunogenic peptide (the modified peptide is SEQ ID NO: 143) result in abolishment of T cell activation.

[0037] [Figure 7] FIG. 1 shows that modifications to the HMW-GS immunogenic peptide (the modified peptide is SEQ ID NO: 146) result in abolishment of T cell activation.

[0038] [Figure 8] FIG. 1 shows that modifications to the HMW-GS immunogenic peptide (the modified peptide is SEQ ID NO: 147) result in abolishment of T cell activation.

[0039] [Figure 9] FIG. 1 shows that modifications to HMW-GS immunogenic peptides (the modified peptides are SEQ ID NOs: 174, 169, 145, 144, and 176) result in abrogation of T cell activation.

[0040] [Figure 10A] FIG. 1 shows the evaluation of specific IgE from sera of wheat-allergic patients against wheat extract and HMW Dy10 (SEQ ID NO: 48 WT; SEQ ID NO: 103 and SEQ ID NO: 169 DE) recombinant proteins: wild type [WT] and de-epitope-modified [DE]. [Figure 10B]Figure 1 shows the assessment of specific IgE from wheat-allergic patient sera to wheat extract and HMW Dx5 (SEQ ID NO: 47 WT; SEQ ID NOs: 128 and 102 DE) recombinant proteins: wild-type [WT] and de-epitope-modified [DE]. Serum specific IgE binding was assessed by a standard ELISA protocol. Recombinant HMW proteins or wheat extracts were immobilized on a solid surface (microplate), and sera from 63 clinically validated wheat-allergic human patients were sampled in triplicate. Data are shown as normalized binding signals: the IgE signal (OD450) of the test serum was divided by the IgE signal (OD450) of the negative control serum on a logarithmic axis. The average normalized binding for recombinant HMW proteins and wheat extracts is shown as black bars. Dunnett's multiple comparison test was performed for all groups against the wheat extract group. **** indicates P≦0.0001, and NS indicates a non-significant p-value. DETAILED DESCRIPTION OF THE INVENTION

[0041] In the following detailed description, numerous specific details are set forth to provide a thorough understanding of the de-epitope-modified high molecular weight (HMW) glutenin polypeptides described herein, methods for producing these HMW glutenin polypeptides, methods for de-epitope-modifying HMW glutenin, and uses of the de-epitope-modified HMW glutenin polypeptides. However, it will be understood by those skilled in the art that the methods for de-epitope-modifying HMW glutenin, the described de-epitope-modified HMW glutenin, methods for producing the de-epitope-modified HMW glutenin, and uses thereof can be practiced without these specific details. In other instances, well-known methods, procedures, and components have not been described in detail so as not to obscure the present disclosure.

[0042] Celiac disease (CD) is a long-term autoimmune disorder that primarily affects the small intestine. Classic symptoms include gastrointestinal problems such as chronic diarrhea, abdominal distension, malabsorption, and loss of appetite, and failure to thrive in children. It often begins between 6 months and 2 years of age. Non-classic symptoms are more common, especially in people over the age of 2. Patients may have mild or no gastrointestinal symptoms, multiple symptoms involving any part of the body, or no obvious symptoms.

[0043] CD is caused by a reaction to gluten, which is found in wheat and other grains such as barley and rye. Gluten is a protein naturally found in some grains, such as wheat, barley, and rye, including HMW glutenin. Exposure to gluten can cause an abnormal immune response, resulting in the production of several different autoantibodies that can affect several different organs. In the small intestine, this can cause an inflammatory response, leading to shortening of the villi lining the small intestine.

[0044] Diagnosis is typically made by a combination of blood antibody testing and intestinal biopsy, aided by specific genetic testing. The disease is caused by a persistent intolerance to wheat proteins, but it is not a form of wheat allergy.

[0045] The methods and uses of depitopied HMW glutenin described herein also relate to other forms of gluten sensitivity. In some aspects, the term "CD" can encompass other forms of gluten sensitivity.

[0046] HMW glutenin proteins contain repeating antigenic units that contain celiac disease (CD)-reactive epitopes. A wide range of repeating antigenic units are contained in HMW glutenin proteins. In some embodiments, HMW glutenin proteins contain 10 to 30 repeating antigenic subunits. In some embodiments, HMW glutenin proteins contain more than 30 repeating antigenic subunits. In certain embodiments, the CD-reactive epitopes correspond to or overlap with IgE allergenic epitopes.

[0047] In some embodiments, de-epitopling of HMW glutenin involves mutation of antigenic units containing CD-associated T cell epitopes. In some embodiments, de-epitopling of HMW glutenin provides HMW glutenin polypeptides with reduced allergenicity. In some embodiments, de-epitopling of HMW glutenin provides HMW glutenin polypeptides with reduced immunogenicity. In some embodiments, de-epitopling of HMW glutenin antigenic units containing these CD-associated T cell epitopes provides hypoallergenic HMW glutenin polypeptides. In some embodiments, these de-epitopled HMW glutenin polypeptides comprise lower binding affinity for T cells and exhibit reduced T cell activation. Thus, these de-epitopled HMW glutenin polypeptides can be used to produce doughs and foods compatible with the diet of human subjects suffering from CD.

[0048] The name HMW-GS appears in the literature as the full name for the HMW-glutenin family of proteins, which divides glutenins into high molecular weight (HMW) and low molecular weight (LMW) subunits, i.e., if you extract all the glutenins from wheat, you can divide them into these two families, these two "subunits".

[0049] In some aspects, as used herein, the terms "HMW glutenin protein," "HMW glutenin polypeptide," "HMW-GS," and "HMW glutenin" are used interchangeably and may all have the same meaning and qualities.

[0050] Those skilled in the art will understand that "high molecular weight glutenin" ("HMW glutenin") can encompass grass gluten proteins containing a repeating motif (e.g., but not limited to, PGQGQQ (SEQ ID NO: 100), GYYPTS[P / L]QQ (SEQ ID NO: 101 and SEQ ID NO: 180), and / or GQQ) and an extensive central elastomeric domain flanked by two terminal non-repeating domains that form disulfide bridges. The repeating motif typically occurs more than 10, more than 15, or even more than 20 times in the protein. Exemplary grasses from which HMW glutenin proteins can be derived include, but are not limited to, wheat (e.g., einkorn), spelt, and barley. In some aspects, the HMW glutenin is wheat high molecular weight glutenin.

[0051] Those skilled in the art will understand that the term "antigenic unit" encompasses repeating antigenic units present in HMW glutenin that contain a CD4-associated T cell epitope. In some embodiments, the term "antigenic unit" encompasses a single antigenic unit that contains a CD4-associated T cell epitope. In some embodiments, the term "antigenic unit" encompasses multiple antigenic units, each containing a CD4-associated T cell epitope. In some embodiments, an "antigenic unit" comprises an HMW glutenin antigenic peptide subunit. In some embodiments, the term "antigenic unit" is used interchangeably with terms such as "repeated antigenic unit." In certain embodiments, an HMW glutenin contains repeating antigenic units, and the amino acid sequences of the repeating units can have between 50% and 100% identity. In some embodiments, the amino acid sequences of the repeating antigenic units contained within an HMW glutenin do not share 100% amino acid sequence identity. In some aspects, the repeating antigenic unit comprises a repeating motif (for example, but not limited to, PGQGQQ (SEQ ID NO: 100), GYYPTS[P / L]QQ (SEQ ID NO: 101 and SEQ ID NO: 180), and / or GQQ).

[0052] Those skilled in the art will understand that the term "epitope" may be used interchangeably with terms such as "antigenic determinant," "CD-associated T-cell epitope," and "CD epitope," all of which have the same meaning and quality, and may encompass a site on an antigen to which a T cell specifically binds.

[0053] T cell epitopes are formed by adjacent amino acids in a protein or peptide. Epitopes formed from adjacent amino acids (linear epitopes) typically retain their structure upon exposure to denaturing solvents. Epitopes typically include at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acids in a unique spatial arrangement. In some embodiments, epitopes are as small as possible while still maintaining immunogenicity. Immunogenicity is demonstrated by the ability to elicit an immune response as described herein, e.g., the ability to bind to an MHC class II molecule and induce a T cell response, e.g., as measured by T cell cytokine production. In some embodiments, the antigenic unit comprises an epitope core.

[0054] The molecules that transport and present peptides on the cell surface are called major histocompatibility complex (MHC) proteins. MHC proteins are classified into two types, MHC class I and MHC class II. Although the structures of the two MHC class proteins are very similar, they have very different functions. MHC class I proteins are present on the surface of almost all cells in the body, including most tumor cells. MHC class I proteins usually carry antigens derived from endogenous proteins or intracellular pathogens and are then presented to naive or cytotoxic T lymphocytes (CTLs). MHC class II proteins are present on dendritic cells, B lymphocytes, macrophages, and other antigen-presenting cells. They primarily present peptides processed from external antigen sources, i.e., from the outside of cells, to T helper (Th) cells. T cell receptors can recognize and bind to peptides complexed with MHC class I or II molecules. Each T lymphocyte expresses a specific T cell receptor that can bind to a specific MHC / peptide complex. In some aspects, the depitopled HMW glutenins or antigenic subunits thereof disclosed herein demonstrate reduced binding to MHC II proteins.

[0055] Antigen-presenting cells (APCs) are cells that present peptide fragments of protein antigens in association with MHC molecules on their cell surface. Some APCs can activate antigen-specific T cells. Examples of APCs include, but are not limited to, dendritic cells, B cells, and macrophages.

[0056] According to some embodiments, the antigenic units disclosed herein comprise a T cell epitope. In some embodiments, the antigenic unit comprises a minimally required T cell epitope. The minimum peptide length, necessary but not necessarily sufficient for binding to MHC II, is 9, since this is the number of amino acids that directly interact with the MHC II binding groove. Lack of binding to MHC II results in the absence of a peptide-MHC II complex recognized by the T cell receptor, which also implicitly makes this a minimum length for T cell activation. In some embodiments, the T cell epitope is a celiac disease-associated epitope (CD-associated epitope)—i.e., the epitope is presented on antigen-presenting cells (APCs) in celiac patients. As used throughout, terms such as "CD-associated T cell epitope" and "CD-associated epitope" are used interchangeably and may all have the same meaning and quality.

[0057] Within a protein sequence, such as the sequence of an HMW glutenin polypeptide, there are continuous CD-associated epitopes, which are linear sequences of amino acids that can be bound by antigen-presenting cells (APCs).

[0058] Those skilled in the art will understand that terms such as "depitope-depleted high molecular weight glutenin," "depitope-depleted HMW glutenin," "modified HMW glutenin," "modified depitope-depleted high molecular weight glutenin," and "modified depitope-depleted HMW glutenin" may be used interchangeably and all have the same qualities and meanings, and that in certain embodiments, depitope-depleted HMW glutenin may encompass modified HMW glutenin that has reduced or abolished binding to APCs, e.g., T cells (compared to T cell binding to its wild-type counterpart), due to mutations in one or more epitopes recognized by T cells.

[0059] In some aspects, the de-epitope-modified HMW glutenins described herein have reduced immunogenicity compared to their wild-type counterparts. For example, celiac disease (CD) is mediated by T cell epitopes that are altered in the de-epitope-modified HMW glutenins to avoid HLA binding and presentation to T cells.

[0060] In some aspects, the digested, de-epitope-modified HMW glutenin described herein has reduced or abolished binding to MHC class II molecules. In some aspects, the de-epitope-modified HMW glutenin described herein has reduced immunogenicity compared to its wild-type counterpart. In some aspects, the de-epitope-modified HMW glutenin described herein is hypoallergenic compared to its wild-type counterpart.

[0061] As used herein, "allergen" can include any substance, protein or non-protein, that can induce an allergy or specific hypersensitivity. In some embodiments, an allergen comprises a HMW glutenin polypeptide.

[0062] As used herein, "allergenicity" or "allergenic" encompasses the ability of an antigen or allergen to induce an aberrant immune response that differs from a normal immune response in that it is an overreaction, does not provide a protective / preventative effect, and instead causes physiological dysfunction or tissue damage. In some aspects, HMW glutenin allergens induce an aberrant immune response that causes disease and / or tissue damage, such as, but not limited to, wheat-dependent exercise-induced anaphylaxis (WDEIA).

[0063] As used herein, "immunogen" can include a molecule that can elicit an immune response.

[0064] As used herein, "immunogenicity" can include the ability or degree to which a substance can stimulate an immune response.

[0065] Thus, one of skill in the art will recognize that "antigenicity" is the ability to specifically bind to the end products of an immune response, such as secreted antibodies and / or surface receptors on T cells, and "immunogenicity" is the ability to induce a humoral and / or cellular immune response. Importantly, not all molecules that are immunogenic are also antigenic, although the reverse is not true.

[0066] As used herein, "hypoallergenic" refers to a substance that has little or reduced potential to cause an allergic reaction. In some embodiments, the depitopened HMW glutenin is hypoallergenic, including reduced or minimal allergic reactions.

[0067] In some embodiments, the present disclosure provides de-epitope HMW glutenins that have been mutated to reduce or eliminate one or more CD4+-associated T cell epitopes. In some embodiments, the mutations do not affect the biophysical and / or functional characteristics of the de-epitope HMW glutenin, such as, but not limited to, the ability of the de-epitope HMW glutenin to contribute to dough elasticity. In some embodiments, the mutations include substitution or deletion mutations. Deletions can include, for example, the removal of a single amino acid important for allergic and / or CD4+-associated responses, or the entire mapped epitope region.

[0068] Six general amino acid side chain classes have been classified, including class I (Cys); class II (Ser, Thr, Ala, Gly); class III (Asn, Asp, Gln, Glu); class IV (His, Arg, Lys); class V (Ile, Leu, Val, Met); and class VI (Phe, Tyr, Trp). Furthermore, Pro may be substituted in variant structures. Conservative amino acid substitution refers to the substitution of an amino acid of one class with an amino acid of the same class. For example, the substitution of Asp with another class III residue, such as Asn, Gln, or Glu, is a conservative substitution. Non-conservative amino acid substitution refers to the substitution of an amino acid of one class with an amino acid of another class; for example, the substitution of the class II residue, Ala, with a class III residue, such as Asp, Asn, Glu, or Gln. Methods for substitution mutagenesis at the nucleotide or amino acid sequence level are well known in the art.

[0069] As used herein, the term "modify" or "modification" refers to changing two or more amino acids in an antigenic unit. In some embodiments, two, three, four, five, six, seven, eight, nine, or more amino acids are modified in an antigenic unit. The changes can be made by substituting or deleting amino acids at one or more positions. The changes can be made using known techniques, such as PCR mutagenesis. In some embodiments, the modifications of the repeating antigenic units involve the same substitution or deletion in each antigenic unit. In other embodiments, the modifications of the repeating antigenic units involve different substitutions or deletions in each antigenic unit.

[0070] Depitope-depleted high molecular weight (HMW) glutenin In some aspects, disclosed herein is a de-epitope-modified high molecular weight (HMW) glutenin comprising a first mutation at position 1 and a second mutation at position 9 of a repeating antigenic unit. In some aspects, disclosed herein is a de-epitope-modified high molecular weight (HMW) glutenin comprising a first mutation at position 1 and a second mutation at position 9 of a repeating antigenic unit, wherein the amino acid sequence of the repeating, unmutated antigenic unit is set forth in any of SEQ ID NOS: 1-33, 35, or 71-99.

[0071] In some aspects, grasses from which the HMW glutenin protein may be derived include, but are not limited to, wheat (e.g., einkorn), spelt, and barley. In one aspect, the HMW glutenin is wheat HMW glutenin. In one aspect, the HMW glutenin is spelt HMW glutenin. In one aspect, the HMW glutenin is barley HMW glutenin.

[0072] Those skilled in the art will understand that HMW glutenin contains repeating antigenic units, and that de-epitopling can involve mutations to individual antigenic units or to multiple antigenic units of the HMW glutenin. In some embodiments, the mutations found in an antigenic unit are the same as those present in another antigenic unit of the HMW glutenin. In some embodiments, the mutations found in an antigenic unit are different from those present in another antigenic unit of the HMW glutenin. In some embodiments, the mutations found in an antigenic unit are different from those present in at least one other antigenic unit of the HMW glutenin and the same as those present in at least one other antigenic unit of the HMW glutenin. In some embodiments, the de-epitopled HMW glutenin contains antigenic units containing different mutations. In some embodiments, the de-epitopled HMW glutenin contains antigenic units containing the same mutations. In some embodiments, the de-epitopled HMW glutenin contains a mixture of antigenic units containing the same mutations and antigenic units containing different mutations.

[0073] In some aspects, a single HMW glutenin comprises multiple repeating antigenic units, and the sequences of the antigenic units can be identical. In some aspects, a single HMW glutenin comprises multiple repeating antigenic units, and the sequences of the antigenic units can be different. In some aspects, a single HMW glutenin comprises multiple repeating antigenic units, and the sequences of the antigenic units include antigenic units with identical sequences and antigenic units with different sequences.

[0074] In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 5 and 30 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 5 and 20 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 5 and 10 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 5 and 15 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 10 and 15 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 10 and 20 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 15 and 20 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 10 and 30 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 15 and 30 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated between about 20 and 30 times. In some embodiments, the repeating antigenic unit comprises more than 30 repeating antigenic units.

[0075] In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than about 5 to 30 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than about 5 to 20 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than about 5 to 10 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than about 5 to 15 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than about 10 to 15 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than about 10 to 20 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than about 15 to 20 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than 10 to 30 times. In some embodiments, the repeating antigenic unit comprises an antigenic unit that is repeated more than 15 to 30 times. In some embodiments, the repeating antigenic unit comprises more than 20 to between 30 repeating antigenic units.

[0076] In some embodiments, the HMW glutenin comprises a grass gluten protein comprising a repeating motif, such as, but not limited to, a sequence set forth as PGQGQQ (SEQ ID NO: 100), GYYPTS[P / L]QQ (SEQ ID NO: 101 and SEQ ID NO: 180), and / or GQQ, and an extensive central elastomeric domain flanked by two terminal non-repeated domains that form disulfide bridges. In some embodiments, the repeating antigenic unit of the HMW glutenin comprises a repeating motif selected from SEQ ID NO: 100, SEQ ID NO: 101, or GQQ.

[0077] In some embodiments, the repeating antigenic unit comprises a tripeptide having the amino acid sequence GQQ. In some embodiments, the repeating antigenic unit comprises a hexapeptide having the amino acid sequence set forth in SEQ ID NO: 100. In some embodiments, the repeating antigenic unit comprises a nonapeptide having the amino acid sequence set forth in SEQ ID NO: 101. In some embodiments, the antigenic unit comprises a known amino acid sequence of an antigenic unit. In some embodiments, the antigenic unit comprises an amino acid sequence similar to a known sequence of an antigenic unit. In some embodiments, the antigenic unit comprises an amino acid sequence having 70-99.9% identity to a known sequence of an HMW glutenin repeating antigenic unit, as determined using the National Center for Biotechnology Information (NCBI) BlastP software using default parameters. In some embodiments, the antigenic unit comprises an amino acid sequence having 70%, 75%, 80%, 85%, 90%, 95%, 97%, or 99% identity to a known sequence of an HMW glutenin repeating antigenic unit.

[0078] In some aspects, the repeating antigenic unit comprises a nonapeptide whose amino acid sequence is selected from the sequences set forth in SEQ ID NOs: 1-33, 35, 71-75, and 77-99. In some aspects, the repeating antigenic unit comprises a dodecapeptide whose amino acid sequence is set forth in SEQ ID NO: 76. In some aspects, the repeating antigenic unit comprises an amino acid sequence selected from the sequences set forth in SEQ ID NOs: 1-33, 35, and 71-99.

[0079] In some embodiments, the antigenic unit comprises a CD-associated epitope, which comprises a determinant recognized by lymphocytes. A CD-associated epitope can be a peptide presented by a major histocompatibility complex (MHC) molecule and capable of specific binding to a T cell receptor. In certain embodiments, a CD epitope is a region of a T cell immunogen that is specifically bound by a T cell receptor. In certain embodiments, a CD epitope can comprise a chemically active surface group of a molecule, such as an amino acid, a sugar side chain, a phosphoryl, or a sulfonyl group. In certain embodiments, a CD epitope can have specific three-dimensional structural characteristics and / or specific charge characteristics.

[0080] In some embodiments, the T cell CD4-associated epitope contained within the repeating antigenic unit may comprise a short peptide that binds to a class II MHC molecule, thereby forming a ternary complex that can be recognized by T cells with a compatible T cell receptor that binds to the MHC / peptide complex with appropriate affinity. T cell epitopes that bind to MHC class II molecules are typically about 12-30 amino acids in length, but may be longer. In the case of peptides that bind to MHC class II molecules, the same peptide and corresponding T cell epitope may share a common core segment but may differ in overall length due to different lengths of flanking sequence upstream of the amino terminus and downstream of its carboxy terminus of the epitope core sequence. A T cell epitope may be classified as immunogenic if it elicits an immune response. In certain embodiments, the T cell CD4-associated epitope of HMW glutenin is present in a repeating antigenic unit. In certain embodiments, the T cell CD4-associated epitope of HMW glutenin is present in a repeating antigenic unit comprising an amino acid sequence set forth in any of SEQ ID NOS: 1-33, 35, or 71-99.

[0081] As used herein, the term "T cell receptor" or "TCR" refers to a complex of membrane proteins that participates in the activation of T cells in response to antigen presentation. TCRs are responsible for recognizing antigens bound to major histocompatibility complex molecules. TCRs are composed of a heterodimer of an alpha (α) chain and a beta (β) chain, although in some cells, the TCR consists of a gamma chain and a delta chain. TCRs can exist in alpha / beta and gamma / delta forms, which are structurally similar but have different anatomical locations and functions. Each chain is composed of two extracellular domains, a variable domain, and a constant domain. TCRs in the present invention can exist in various forms, including different fragments of the TCR.

[0082] The term "T cell immunogen" refers to an agent (e.g., a protein or portion thereof) that can elicit a T cell-mediated immune response. In some embodiments, a CD-associated T cell immunogen comprises at least one T cell CD epitope. In some embodiments, the T cell immunogen comprises a wheat protein or portion thereof, such as a gluten protein. In some embodiments, the T cell immunogen comprises HMW glutenin from wheat.

[0083] In certain embodiments in which the CD4-associated T cell epitope is the same as or overlaps with an epitope of IgE-binding wheat allergy, the antigenic unit comprises a determinant recognized by IgE antibodies derived from serum obtained from a human subject suffering from wheat allergy.

[0084] Those skilled in the art will understand that antibody (Ab) epitopes can be formed from both adjacent and non-adjacent amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from adjacent amino acids (linear epitopes) are typically retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding (conformational epitopes) are typically lost upon treatment with denaturing solvents. An epitope typically contains at least 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 amino acids in a unique spatial arrangement. Allergenicity to an epitope is indicated by its ability to induce allergen-specific IgE antibodies in susceptible individuals (subjects suffering from wheat allergy). In some embodiments, the antigenic unit comprises an epitope core. Within a protein sequence, e.g., the sequence of an HMW glutenin polypeptide, there are continuous epitopes, which are linear sequences of amino acids that can be bound by an antibody, or discontinuous epitopes, which can also be bound by an antibody but are only present when the protein is folded into a particular conformation. In certain embodiments, the repeating antigenic units comprise those set forth in any of SEQ ID NOS: 1-33 or 35. In certain embodiments, the repeating antigenic units comprise those set forth in any of SEQ ID NOS: 71-99. In certain embodiments, the repeating antigenic units comprise those set forth in any of SEQ ID NOS: 1-33, 35, or 71-99. In certain embodiments, the repeating antigenic units comprise the amino acid sequence set forth in SEQ ID NO: 1 (Figure 1A, boxed antigenic unit).

[0085] In some embodiments, the non-depitopinated HMW glutenin comprises wild-type (WT) HMW glutenin. In some embodiments, the amino acid sequence of the non-depitopinated HMW glutenin is selected from the sequences set forth in SEQ ID NOS: 43-48 and 152-154 (FIGS. 1A-1I). In some embodiments, the amino acid sequence of the non-depitopinated HMW glutenin is selected from the sequences having at least 50% identity to the amino acid sequences set forth in SEQ ID NOS: 43-48 and 152-154. In some embodiments, the amino acid sequence of the non-depitopinated HMW glutenin is selected from the sequences having at least 50% to 99% identity to the sequences set forth in SEQ ID NOS: 43-48 and 152-154. In some embodiments, the amino acid sequence of the non-depitopened HMW glutenin is selected from a sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or even 99% identity to any of the amino acid sequences set forth in SEQ ID NOs: 43-48 and 152-154. In some embodiments, the amino acid sequence of the non-depitopened HMW glutenin is selected from a sequence set forth in SEQ ID NOs: 43-48 and 152-154, or an amino acid sequence having at least 50% identity to any of the sequences set forth in SEQ ID NOs: 43, 44, 45, 46, 47, 48, 152, 153, and 154.

[0086] The "percent identity" of two amino acid sequences can be determined using the algorithm of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, modified as in Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-77, 1993. Such an algorithm has been incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul et al., J. Mol. Biol. 215:403-10, 1990. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3, to obtain amino acid sequences homologous to a protein molecule of interest. When gaps exist between the two sequences, Gapped BLAST can be utilized as described in Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1997. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. BLAST nucleotide searches can be performed using the NBLAST nucleotide program parameters set, for example, to score = 100 and word length = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed using the XBLAST program parameters set, for example, to score 50 and word length = 3 to obtain amino acid sequences homologous to the protein molecules described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul SF et al. (1997) Nuc Acids Res 25:3389-3402. Alternatively, PSI BLAST or PHI BLAST can be used to perform an iterated search that detects distant relationships (Id.) between molecules.When utilizing BLAST, Gapped BLAST, PSI Blast, and PHI Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used (see, e.g., the National Center for Biotechnology Information (NCBI) on the World Wide Web at ncbi(dot)nlm(dot)nih(dot)gov). Another specific, non-limiting example of a mathematical algorithm utilized for sequence comparison is the algorithm of Myers and Miller, 1988, CABIOS 4:11 17. Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program to compare amino acid sequences, a PAM 120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps, as can be used with any software for protein sequence alignment. In calculating percent identity, typically, only exact matches are counted.

[0087] In some aspects, the non-depitopeed HMW glutenin polypeptide comprises an amino acid sequence that is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80%, at least 85%, at least 90%, or at least 95%, or at least 99% identical to a polypeptide set forth in any of SEQ ID NOs: 43-48 and 152-154, as determined using the BlastP software of the National Center for Biotechnology Information (NCBI) using default parameters.

[0088] In certain aspects, the modified depitope-modified HMW glutenins disclosed herein have a sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of the sequences set forth in SEQ ID NOs: 43-48 and 152-154.

[0089] Those skilled in the art will understand that the term "modified" as used herein to describe HMW glutenin encompasses the depitopled HMW glutenin disclosed herein. In some aspects, terms such as "modified HMW glutenin," "modified depitopled glutenin," and "depitoped glutenin" may all be used interchangeably and have the same meaning and qualities.

[0090] In some aspects, the de-epitopeed HMW glutenin disclosed herein comprises a protein comprising at least two mutations in at least one repeating antigenic unit identified as containing a CD4-associated T-cell epitope, wherein the de-epitopeed HMW glutenin protein binds to its associated MHC protein with a lower affinity than the wild-type counterpart, and / or the de-epitopeed HMW glutenin protein activates T cells to a lesser extent than the wild-type counterpart, as described further herein below. In some aspects, the de-epitopeed HMW glutenin disclosed herein comprises a protein comprising at least two amino acid deletion mutations in at least one repeating antigenic unit identified as containing a CD4-associated T-cell epitope, wherein the de-epitopeed HMW glutenin protein binds to its associated MHC protein with a lower affinity than the wild-type counterpart, and / or the de-epitopeed HMW glutenin protein activates T cells to a lesser extent than the wild-type counterpart, as described further herein below. In some aspects, the de-epitopeed HMW glutenin disclosed herein comprises a protein comprising at least two substitution mutations within at least one repeating antigenic unit identified as containing a CD4-associated T cell epitope, wherein the de-epitopeed HMW glutenin protein binds to its associated MHC protein with lower affinity than its wild-type counterpart and / or the de-epitopeed HMW glutenin protein activates T cells to a lesser extent than its wild-type counterpart, as further described herein below.

[0091] In certain aspects, the protein comprises mutations in at least two repeating antigenic units, at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 antigenic units. In some aspects, the protein comprises mutations in more than two repeating antigenic units, more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units. In some aspects, the protein comprises mutations in 2 repeating antigenic units, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units. In some aspects, the protein comprises mutations in all repeating antigenic units. In some aspects, the protein comprises deletions of all repeating antigenic units.

[0092] In some embodiments, the protein comprises mutations in 1 to 30 antigenic units. In some embodiments, the protein comprises mutations in 1 to 20 antigenic units. In some embodiments, the protein comprises mutations in 1 to 5 antigenic units. In some embodiments, the protein comprises mutations in 1 to 10 antigenic units. In some embodiments, the protein comprises mutations in 1 to 15 antigenic units. In some embodiments, the protein comprises mutations in 10 to 15 antigenic units. In some embodiments, the protein comprises mutations in 5 to 20 antigenic units. In some embodiments, the protein comprises mutations in 5 to 10 antigenic units. In some embodiments, the protein comprises mutations in 5 to 15 antigenic units. In some embodiments, the protein comprises mutations in 10 to 20 antigenic units. In some embodiments, the protein comprises mutations in 15 to 20 antigenic units. In some embodiments, the protein comprises mutations in more than 20 antigenic units. In some embodiments, the protein comprises between more than 5 and 30 mutations. In some embodiments, the protein comprises between more than 10 and 30 mutations. In some embodiments, the protein comprises between more than 15 and 30 mutations. In some embodiments, the protein comprises between more than 20 and 30 mutations. In some embodiments, the protein comprises between more than 5 and 30 mutations.

[0093] In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or all of the antigenic units present in the de-epitope-modified HMW glutenin protein are mutated (i.e., de-epitope-modified). In some embodiments, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or all of the antigenic units present in the de-epitope-modified HMW glutenin protein are mutated.

[0094] In some embodiments, the de-epitope HMW glutenin proteins described herein contain at least one essential physical property that is also present in their wild-type counterparts. Thus, for example, in the case of HMW glutenin, the de-epitope HMW glutenin has beneficial properties that contribute to dough elasticity. Other examples of beneficial properties include the ability of HMW glutenin to promote dough leavening and the ability of HMW glutenin to strengthen dough.

[0095] In some embodiments, the de-epitopeed HMW glutenin comprises a mutation within a repeating antigenic unit, ie, a mutation of one or more amino acid residues of a wheat HMW glutenin polypeptide, wherein the mutation is within one or more identified or proposed CD-associated epitopes.

[0096] In some embodiments, the HMW glutenin comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 or more mutations of amino acid residues comprising repeating antigenic units of the HMW glutenin polypeptide. In some embodiments, one or more mutations disrupt one or more (or all) of identified T cell CD4+-associated epitopes on the polypeptide (i.e., the mutations cause the T cell CD4+-associated epitope to bind to its associated MHC protein with a lower affinity than its wild-type counterpart and / or activate T cells to a lesser extent than its wild-type counterpart).

[0097] In some embodiments, the de-epitope-modified HMW glutenin comprises a first mutation at position 1 of the repeating antigenic unit and a second mutation at position 9. In some embodiments, the de-epitope-modified HMW glutenin comprises a first mutation and a second mutation as any of positions 1-9 of the repeating antigenic unit.

[0098] Methods for generating polypeptides containing one or more mutations are well known to those skilled in the art. In some embodiments, one or more mutations are conservative mutations. In some embodiments, one or more mutations are non-conservative mutations. In some embodiments, one or more mutations are a mixture of conservative and non-conservative mutations.

[0099] In some aspects, the one or more mutations comprise substitutions, deletions, or insertions, or a combination thereof. In some aspects, the mutations within the antigenic unit comprise substitutions. In some aspects, the mutations within the antigenic unit comprise deletions. In some aspects, the mutations within the antigenic unit comprise insertions. One skilled in the art will understand that one antigenic unit may comprise a particular mutation, while another antigenic unit may comprise a different mutation.

[0100] In some embodiments, the deletion mutation comprises deleting at least one amino acid from the repeating antigenic unit, two amino acids from the repeating antigenic unit, three amino acids from the repeating antigenic unit, four amino acids from the repeating antigenic unit, five amino acids from the repeating antigenic unit, six amino acids from the repeating antigenic unit, seven amino acids from the repeating antigenic unit, eight amino acids from the repeating antigenic unit, or all amino acids from the repeating unit. In some embodiments, the deletion mutation comprises deleting a repeating antigenic unit.

[0101] In some embodiments, at least 20% of the repeating antigenic units are completely deleted, at least 30% of the repeating antigenic units are completely deleted, at least 40% of the repeating antigenic units are completely deleted, at least 50% of the repeating antigenic units are completely deleted, at least 60% of the repeating antigenic units are completely deleted, at least 70% of the repeating antigenic units are completely deleted, at least 80% of the repeating antigenic units are completely deleted, or at least 90% of the repeating antigenic units are completely deleted, hi some embodiments, all of the repeating antigenic units are completely deleted.

[0102] In some aspects, the antigenic unit of the de-epitope-modified HMW glutenin comprises a first mutation at position 1 and a second mutation at position 9, wherein the first mutation, or the second mutation, or both, comprise deletion mutations.

[0103] In some embodiments, the HMW glutenin comprises a deletion mutation of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or all of the amino acid residues within the repeating antigenic unit of the HMW glutenin polypeptide. In some embodiments, the deletion disrupts one or more (or all) of the identified T cell CD4+-associated epitopes on the polypeptide (i.e., the mutation causes the T cell CD4+-associated epitope to bind to its associated MHC protein with a lower affinity than its wild-type counterpart and / or activates T cells to a lesser extent than its wild-type counterpart).

[0104] In some embodiments, the de-epitopeed HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOS: 102-107, 167-168, or 170-172. In some embodiments, all of the repeating antigenic units of the de-epitopeed HMW glutenin set forth in any of SEQ ID NOS: 102-107, 167-168, or 170-172 are completely deleted. In some embodiments, the amino acid sequence of the de-epitopeed high molecular weight glutenin is 90% identical, 91% identical, 92% identical, 93% identical, 94% identical, 95% identical, 96% identical, 97% identical, 98% identical, or 99% identical to any one of the sequences set forth in SEQ ID NOS: 102-107, 167-168, or 170-172, where all repeating units are completely deleted, and identity is determined using the National Center for Biotechnology Information (NCBI) BlastP software or a similar software program using default parameters.

[0105] In some aspects, the antigenic unit of the de-epitope-modified HMW glutenin comprises a first mutation at position 1 and a second mutation at position 9, wherein the first mutation, or the second mutation, or both, comprise a substitution mutation.

[0106] In some embodiments, at least one ninth amino acid of an antigenic unit is replaced with a positively charged amino acid or a small amino acid. In some embodiments, at least two ninth amino acids of an antigenic unit are replaced with positively charged amino acids or small amino acids. In some embodiments, at least three ninth amino acids of an antigenic unit are replaced with positively charged amino acids or small amino acids. In some embodiments, the ninth amino acid of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with a positively charged amino acid or a small amino acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with a positively charged amino acid or a small amino acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 antigenic units is replaced with a positively charged amino acid or a small amino acid.

[0107] In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all 9th ​​amino acids of the antigenic units are replaced with a positively charged amino acid or a small amino acid.

[0108] As used herein, the term "positively charged amino acid" encompasses histidine, lysine, and arginine. In some aspects, the positively charged amino acid is arginine. In some aspects, the positively charged amino acid is histidine. In some aspects, the positively charged amino acid is arginine or histidine. In some aspects, the positively charged amino acid is lysine.

[0109] As used herein, the term "small amino acid" encompasses serine, threonine, alanine, glycine, and valine. In some aspects, a small amino acid is serine. In some aspects, a small amino acid is threonine. In some aspects, a small amino acid is alanine. In some aspects, a small amino acid is glycine. In some aspects, a small amino acid is valine.

[0110] In some embodiments, at least one ninth amino acid of the antigenic unit is replaced with threonine, serine, arginine, histidine, or glutamic acid. In some embodiments, at least two ninth amino acids of the antigenic unit are replaced with threonine, serine, arginine, histidine, or glutamic acid. In some embodiments, at least three ninth amino acids of the antigenic unit are replaced with threonine, serine, arginine, histidine, or glutamic acid. In some aspects, the ninth amino acid of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with threonine, serine, arginine, histidine, or glutamic acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with threonine, serine, arginine, histidine, or glutamic acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 antigenic units is replaced with threonine, serine, arginine, histidine, or glutamic acid.

[0111] In some embodiments, the ninth amino acid of at least one antigenic unit is replaced with threonine or glutamic acid. In some embodiments, the ninth amino acid of at least two antigenic units is replaced with threonine or glutamic acid. In some embodiments, the ninth amino acid of at least three antigenic units is replaced with threonine or glutamic acid. In some embodiments, the ninth amino acid of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with threonine or glutamic acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with threonine or glutamic acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 antigenic units is replaced with threonine or glutamic acid.

[0112] In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all of the ninth amino acids of the antigenic units are replaced with threonine or glutamic acid, hi some embodiments, at least 50%, 60%, 70%, 80%, 90% or all of the ninth amino acids of the antigenic units are replaced with threonine, serine, arginine, histidine or glutamic acid.

[0113] In some embodiments, the ninth amino acid of at least one antigenic unit is replaced with arginine, histidine, threonine, or glutamic acid. In some embodiments, the ninth amino acid of at least two antigenic units is replaced with arginine, histidine, threonine, or glutamic acid. In some embodiments, the ninth amino acid of at least three antigenic units is replaced with arginine, histidine, threonine, or glutamic acid. In some embodiments, the ninth amino acid of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with arginine, histidine, threonine, or glutamic acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with arginine, histidine, threonine, or glutamic acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 antigenic units is replaced with arginine, histidine, threonine, or glutamic acid.

[0114] In some embodiments, at least 50%, 60%, 70%, 80%, 90%, or all 9th ​​amino acids of the antigenic units are replaced with arginine, histidine, threonine, or glutamic acid.

[0115] In some embodiments, the ninth amino acid of at least one antigenic unit is replaced with histidine or arginine. In some embodiments, the ninth amino acid of at least two antigenic units is replaced with histidine or arginine. In some embodiments, the ninth amino acid of at least three antigenic units is replaced with histidine or arginine. In some embodiments, the ninth amino acid of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with histidine or arginine. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with histidine or arginine. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 antigenic units is replaced with histidine or arginine.

[0116] In some aspects, at least 50%, 60%, 70%, 80%, 90%, or all 9th ​​amino acids of the antigenic units are replaced with histidine or arginine.

[0117] In some embodiments, more than one ninth amino acid of an antigenic unit is replaced with arginine, histidine, threonine, or glutamic acid. In some embodiments, more than two ninth amino acids of an antigenic unit are replaced with arginine, histidine, threonine, or glutamic acid. In some embodiments, more than three ninth amino acids of an antigenic unit are replaced with arginine, histidine, threonine, or glutamic acid. In some embodiments, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 antigenic units is replaced with arginine, histidine, threonine, or glutamic acid. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with arginine, histidine, threonine, or glutamic acid.

[0118] In some aspects, more than 50%, 60%, 70%, 80%, 90%, or all 9th ​​amino acids of the antigenic units are replaced with arginine, histidine, threonine, or glutamic acid.

[0119] In some embodiments, the ninth amino acid of at least one antigenic unit is replaced with serine. In some embodiments, the ninth amino acid of at least two antigenic units is replaced with serine. In some embodiments, the ninth amino acid of at least three antigenic units is replaced with serine. In some embodiments, the ninth amino acid of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with serine. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units is replaced with serine. In some aspects, the ninth amino acid of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 antigenic units is replaced with serine.

[0120] In some aspects, at least 50%, 60%, 70%, 80%, 90%, or all 9th ​​amino acids of the antigenic units are replaced with serine.

[0121] In some embodiments of the depitope-modified HMW glutenins disclosed herein, the second mutation (position 9) comprises a substitution mutation that replaces the amino acid residue at position 9 of the repeating antigenic unit with a positively charged amino acid or a small amino acid; or glutamic acid; or a combination thereof when two or more repeating antigenic units are mutated.

[0122] In some embodiments of the depitope-modified HMW glutenins disclosed herein, the second mutation (position 9) comprises a substitution mutation comprising replacement with arginine or histidine; or serine or threonine; or a combination thereof if two or more repeating antigenic units are mutated.

[0123] In some embodiments of the depitope-modified HMW glutenins disclosed herein, the first mutation (position 1) comprises a substitution mutation in which at least one first amino acid of the repeating antigenic unit is replaced with histidine, proline, serine, alanine, lysine, or glutamic acid. In some embodiments, at least one first amino acid of the repeating antigenic unit is replaced with histidine. In some embodiments, at least one first amino acid of the repeating antigenic unit is replaced with proline. In some embodiments, at least one first amino acid of the repeating antigenic unit is replaced with serine. In some embodiments, at least one first amino acid of the repeating antigenic unit is replaced with alanine. In some embodiments, at least one first amino acid of the repeating antigenic unit is replaced with lysine. In some embodiments, at least one first amino acid of the repeating antigenic unit is replaced with glutamic acid.

[0124] In some embodiments of the depitope-modified HMW glutenin disclosed herein, the first mutation comprises a substitution mutation in which at least two first amino acids of the repeating antigenic unit are replaced with histidine, proline, serine, alanine, lysine, or glutamic acid. In some embodiments, at least two first amino acids of the repeating antigenic unit are replaced with histidine. In some embodiments, at least two first amino acids of the repeating antigenic unit are replaced with proline. In some embodiments, at least two first amino acids of the repeating antigenic unit are replaced with serine. In some embodiments, at least two first amino acids of the repeating antigenic unit are replaced with alanine. In some embodiments, at least two first amino acids of the repeating antigenic unit are replaced with lysine. In some embodiments, at least two first amino acids of the repeating antigenic unit are replaced with glutamic acid.

[0125] In some embodiments of the depitope-modified HMW glutenins disclosed herein, the first mutation comprises a substitution mutation in which at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 first amino acids of the repeating antigenic unit are replaced with histidine, proline, serine, alanine, lysine, or glutamic acid. In some aspects, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 first amino acids of the repeating antigenic unit are replaced with histidine, hi some aspects, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 first amino acids of the repeating antigenic unit are replaced with proline. In some aspects, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 first amino acids of the repeating antigenic units are replaced with serine, hi some aspects, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 first amino acids of the repeating antigenic units are replaced with alanine. In some aspects, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 first amino acids of the repeating antigenic units are replaced with lysine. In some aspects, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 first amino acids of the repeating antigenic units are replaced with glutamic acid.

[0126] In some embodiments of the substitution mutation of the repeating antigenic unit contained in the de-epitope-modified HMW glutenin, the substitution is (i) substitution of histidine at position 1 of the antigenic unit and substitution of histidine at position 9 of the antigenic unit; (ii) substitution of proline at position 1 of the antigenic unit and substitution of arginine at position 9 of the antigenic unit; (iii) substitution of alanine at position 1 of the antigenic unit and substitution of arginine at position 9 of the antigenic unit; (iv) substitution of serine at position 1 of the antigenic unit and threonine at position 9 of the antigenic unit; (v) substitution of glutamic acid at position 1 of the antigenic unit and substitution of glutamic acid at position 9 of the antigenic unit; (vi) substitution of proline at position 1 of the antigenic unit and substitution of threonine at position 9 of the antigenic unit; (vii) the substitution at position 1 of the antigenic unit is with glutamic acid and the substitution at position 9 of the antigenic unit is with lysine or arginine; or (viii) the substitution at position 1 of the antigenic unit is with glutamic acid or lysine and the substitution at position 9 of the antigenic unit is with histidine; or (ix) When two or more repeating antigenic units are mutated, any combination of (i) to (viii) Includes.

[0127] In some aspects, the depitope-modified HMW glutenins disclosed herein comprise a mutation at position 1 of the repeating antigenic unit, wherein the mutation comprises a substitution mutation that replaces the amino acid residue at position 1 of the repeating antigenic unit with histidine, proline, serine, alanine, lysine, or glutamic acid.

[0128] In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, - said substitution at position 1 of said antigenic unit is a substitution with histidine and said substitution at position 9 of said antigenic unit is a substitution with histidine; - said substitution at position 1 of said antigenic unit is a substitution with proline and said substitution at position 9 of said antigenic unit is a substitution with arginine; - said substitution at position 1 of said antigenic unit is a substitution with alanine and said substitution at position 9 of said antigenic unit is a substitution with arginine; - said substitution at position 1 of said antigenic unit is a substitution with serine and said substitution at position 9 of said antigenic unit is a substitution with threonine; - said substitution at position 1 of said antigenic unit is a replacement with glutamic acid and said substitution at position 9 of said antigenic unit is a replacement with glutamic acid; - said substitution at position 1 of said antigenic unit is a substitution with proline and said substitution at position 9 of said antigenic unit is a substitution with threonine; - said substitution at position 1 of said antigenic unit is a substitution with glutamic acid and said substitution at position 9 of said antigenic unit is a substitution with lysine or arginine; or - said substitution at position 1 of said antigenic unit is a substitution with glutamic acid or lysine and said substitution at position 9 of said antigenic unit is a substitution with histidine; or - If two or more repeating antigenic units are mutated, any combination of (i) to (viii).

[0129] In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, wherein the substitution at position 1 of the antigenic unit is a replacement with histidine and the substitution at position 9 of the antigenic unit is a replacement with histidine. In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, wherein the substitution at position 1 of the antigenic unit is a replacement with proline and the substitution at position 9 of the antigenic unit is a replacement with arginine. In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, wherein the substitution at position 1 of the antigenic unit is a replacement with alanine and the substitution at position 9 of the antigenic unit is a replacement with arginine. In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, wherein the substitution at position 1 of the antigenic unit is a replacement with serine and the substitution at position 9 of the antigenic unit is a replacement with threonine. In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, wherein the substitution at position 1 of the antigenic unit is a replacement with glutamic acid and the substitution at position 9 of the antigenic unit is a replacement with glutamic acid. In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, wherein the substitution at position 1 of the antigenic unit is a replacement with proline and the substitution at position 9 of the antigenic unit is a replacement with threonine. In some aspects, the depitope-modified HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, wherein the substitution at position 1 of the antigenic unit is a replacement with glutamic acid and the substitution at position 9 of the antigenic unit is a replacement with lysine or arginine.In some aspects, the de-epitopeed HMW glutenins disclosed herein comprise mutations at positions 1 and 9 of the repeating antigenic unit, wherein the substitution at position 1 of the antigenic unit is a replacement with glutamic acid or lysine, and the substitution at position 9 of the antigenic unit is a replacement with histidine.

[0130] In some aspects, the antigenic unit comprises a first mutation at position 1 and a second mutation at position 9, wherein the first mutation, or the second mutation, or both, comprise an insertion mutation.

[0131] In some embodiments, the de-epitope-modified HMW glutenins disclosed herein having mutations at positions 1 and 9 further comprise additional mutations within the repeating antigenic unit, and positions at which additional substitutions can be made include positions 3, 4, and 7. In some embodiments, the de-epitope-modified HMW glutenins having mutations at positions 1 and 9 further comprise at least two additional mutations within the repeating antigenic unit, and positions at which at least two substitutions can be made include positions 3, 4, and 7. In some embodiments, the de-epitope-modified HMW glutenins having mutations at positions 1 and 9 further comprise three additional mutations within the repeating antigenic unit, and positions at which three substitutions can be made include positions 3, 4, and 7.

[0132] In some embodiments, at least one third amino acid of an antigenic unit may be replaced with a positively charged or polar amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 third amino acids of an antigenic unit may be replaced with a positively charged or polar amino acid. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all third amino acids of an antigenic unit may be replaced with a positively charged or polar amino acid.

[0133] In some embodiments, at least one third amino acid of an antigenic unit may be replaced with a positively charged amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 third amino acids of an antigenic unit may be replaced with positively charged amino acids. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all third amino acids of an antigenic unit may be replaced with positively charged amino acids.

[0134] In some embodiments, at least one third amino acid of an antigenic unit may be replaced with a polar amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 third amino acids of an antigenic unit may be replaced with a polar amino acid. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all third amino acids of an antigenic unit may be replaced with a polar amino acid.

[0135] In some embodiments of the de-epitope-modified HMW glutenin, at least one amino acid at position 4 of an antigenic unit may be replaced with a negatively charged amino acid or glycine. In some embodiments of the de-epitope-modified HMW glutenin, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids at position 4 of an antigenic unit may be replaced with a negatively charged amino acid or glycine. In some embodiments of the de-epitope-modified HMW glutenin, at least 50%, 60%, 70%, 80%, 90% or all amino acids at position 4 of an antigenic unit may be replaced with a negatively charged amino acid or glycine.

[0136] In some embodiments of the de-epitope-modified HMW glutenin, at least one amino acid at position 4 of an antigenic unit may be replaced with a negatively charged amino acid. In some embodiments of the de-epitope-modified HMW glutenin, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids at position 4 of an antigenic unit may be replaced with a negatively charged amino acid. In some embodiments of the de-epitope-modified HMW glutenin, at least 50%, 60%, 70%, 80%, 90%, or all amino acids at position 4 of an antigenic unit may be replaced with a negatively charged amino acid.

[0137] In some embodiments of the de-epitope-modified HMW glutenin, the amino acid at position 4 of at least one antigenic unit may be replaced with glycine. In some embodiments of the de-epitope-modified HMW glutenin, the amino acid at position 4 of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 antigenic units may be replaced with glycine. In some embodiments of the de-epitope-modified HMW glutenin, the amino acids at position 4 of at least 50%, 60%, 70%, 80%, 90%, or all antigenic units may be replaced with glycine.

[0138] In some embodiments of the de-epitope-modified HMW glutenin, at least one seventh amino acid of an antigenic unit may be replaced with glycine. In some embodiments of the de-epitope-modified HMW glutenin, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 seventh amino acids of an antigenic unit may be replaced with glycine. In some embodiments of the de-epitope-modified HMW glutenin, at least 50%, 60%, 70%, 80%, 90%, or all seventh amino acids of an antigenic unit are replaced with glycine.

[0139] In some embodiments of the de-epitope-modified HMW glutenin, two or more of the seventh amino acids of an antigenic unit may be replaced with glycine. In some embodiments of the de-epitope-modified HMW glutenin, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 of the seventh amino acids of an antigenic unit may be replaced with glycine. In some embodiments of the de-epitope-modified HMW glutenin, more than 50%, 60%, 70%, 80%, 90% or all of the seventh amino acids of an antigenic unit are replaced with glycine.

[0140] In some embodiments of the de-epitope-modified HMW glutenin, the seventh amino acid of one of the antigenic units may be replaced with glycine. In some embodiments of the de-epitope-modified HMW glutenin, the seventh amino acid of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the antigenic units may be replaced with glycine. In some embodiments of the de-epitope-modified HMW glutenin, 50%, 60%, 70%, 80%, 90% or all of the seventh amino acids of the antigenic units are replaced with glycine.

[0141] As used herein, the term "polar amino acids" can include the amino acids serine, threonine, tyrosine, asparagine, and glutamine. In some aspects, polar amino acids include serine. In some aspects, polar amino acids include threonine. In some aspects, polar amino acids include asparagine. In some aspects, polar amino acids include tyrosine.

[0142] As used herein, the term "negatively charged" encompasses aspartic acid and glutamic acid. In some aspects, the negatively charged amino acid is aspartic acid. In some aspects, the negatively charged amino acid is glutamic acid.

[0143] In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise at least two additional substitution mutations at any of positions 3, 4, and 7 of the repeating antigenic unit. In some aspects, the de-epitope-modified HMW glutenins disclosed herein comprise three additional substitution mutations at positions 3, 4, and 7 of the repeating antigenic unit.

[0144] In some embodiments, the de-epitope-modified HMW glutenins disclosed herein comprise at least two additional substitution mutations at any of positions 3, 4, and 7, including a substitution at position 3 with a polar or positively charged amino acid, or a substitution at position 4 with a negatively charged amino acid or glycine, or a substitution at position 7 with glycine, or any combination thereof. In some embodiments, the de-epitope-modified HMW glutenins disclosed herein comprise three additional substitution mutations at positions 3, 4, and 7, including a substitution at position 3 with a polar or positively charged amino acid, a substitution at position 4 with a negatively charged amino acid or glycine, and a substitution at position 7 with glycine.

[0145] In some aspects, the de-epitopeed HMW glutenins disclosed herein contain additional mutations within the repeating antigenic unit, and positions where additional substitutions can be made include positions 2, 3, and 8.

[0146] In some embodiments, at least one second amino acid of an antigenic unit may be replaced with an aromatic amino acid or a positively charged amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 second amino acids of an antigenic unit may be replaced with an aromatic amino acid or a positively charged amino acid. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all second amino acids of an antigenic unit may be replaced as described above.

[0147] In some embodiments, two or more second amino acids of an antigenic unit may be replaced with aromatic amino acids or positively charged amino acids. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 second amino acids of an antigenic unit may be replaced with aromatic amino acids or positively charged amino acids. In some embodiments, more than 50%, 60%, 70%, 80%, 90% or all of the second amino acids of an antigenic unit may be replaced as described above.

[0148] In some embodiments, one second amino acid of an antigenic unit may be replaced with an aromatic amino acid or a positively charged amino acid. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 second amino acids of an antigenic unit may be replaced with an aromatic amino acid or a positively charged amino acid. In some embodiments, 50%, 60%, 70%, 80%, 90% or all of the second amino acids of an antigenic unit may be replaced as described above.

[0149] In some embodiments, at least one third amino acid of an antigenic unit may be replaced with a polar or positively charged amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 third amino acids of an antigenic unit may be replaced with a polar or positively charged amino acid. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all third amino acids of an antigenic unit may be replaced as described above.

[0150] In some embodiments, two or more third amino acids of an antigenic unit may be replaced with polar or positively charged amino acids. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 third amino acids of an antigenic unit may be replaced with polar or positively charged amino acids. In some embodiments, more than 50%, 60%, 70%, 80%, 90% or all of the third amino acids of an antigenic unit may be replaced as described above.

[0151] In some embodiments, one third amino acid of an antigenic unit may be replaced with a polar or positively charged amino acid. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 third amino acids of an antigenic unit may be replaced with a polar or positively charged amino acid. In some embodiments, 50%, 60%, 70%, 80%, 90% or all of the third amino acids of an antigenic unit may be replaced as described above.

[0152] In some embodiments, at least one eighth amino acid of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 eighth amino acids of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all eighth amino acids of an antigenic unit may be replaced as described above.

[0153] In some aspects, two or more eighth amino acids of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some aspects, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 eighth amino acids of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some aspects, more than 50%, 60%, 70%, 80%, 90% or all eighth amino acids of an antigenic unit may be replaced as described herein.

[0154] In some embodiments, one eighth amino acid of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 eighth amino acids of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some embodiments, 50%, 60%, 70%, 80%, 90% or all eighth amino acids of an antigenic unit may be replaced as described above.

[0155] In some embodiments, the amino acid at position 2 is replaced with tryptophan and the amino acid at position 3 is replaced with histidine.

[0156] As used herein, the term "aliphatic amino acid" can include the amino acids methionine, valine, leucine, isoleucine, and alanine. In some aspects, an aliphatic amino acid comprises methionine. In some aspects, an aliphatic amino acid comprises valine. In some aspects, an aliphatic amino acid comprises leucine. In some aspects, an aliphatic amino acid comprises isoleucine. In some aspects, an aliphatic amino acid comprises alanine.

[0157] As used herein, the term "aromatic amino acid" can encompass the amino acids phenylalanine, tryptophan, and tyrosine. In some aspects, aromatic amino acids include phenylalanine. In some aspects, aromatic amino acids include tryptophan. In some aspects, aromatic amino acids include tyrosine.

[0158] In some embodiments, the de-epitope-modified HMW glutenin disclosed herein having mutations at positions 1 and 9 further comprises at least two additional substitution mutations at any of positions 2, 3, and 8 of the repeating antigenic unit. In some embodiments, the de-epitope-modified HMW glutenin having mutations at positions 1 and 9 further comprises at least two additional substitution mutations at any of positions 2, 3, and 8, where the substitution at position 2 is an aromatic amino acid or a positively charged amino acid; or the substitution at position 3 is a polar amino acid or a positively charged amino acid; or the substitution at position 8 is to a small amino acid or an aliphatic amino acid; or any combination thereof. In some embodiments, the de-epitope-modified HMW glutenin having mutations at positions 2, 3, and 8 further comprises at least two additional substitution mutations at any of positions 2, 3, and 8, where the substitution at position 2 is tryptophan and the substitution at position 3 is histidine.

[0159] In some embodiments, the de-epitope-modified HMW glutenin disclosed herein with mutations at positions 1 and 9 comprises three additional substitution mutations at positions 2, 3, and 8 of the repeating antigenic unit. In some embodiments, the de-epitope-modified HMW glutenin with mutations at positions 1 and 9 comprises three additional substitution mutations at positions 2, 3, and 8, wherein the substitution at position 2 is an aromatic amino acid or a positively charged amino acid; or the substitution at position 3 is a polar amino acid or a positively charged amino acid; or the substitution at position 8 is to a small amino acid or an aliphatic amino acid; or any combination thereof. In some embodiments, the de-epitope-modified HMW glutenin comprising mutations at positions 1 and 9 comprises at least three additional substitution mutations at positions 2, 3, and 8, wherein the substitution at position 2 is tryptophan and the substitution at position 3 is histidine.

[0160] In some aspects, the de-epitopeed HMW glutenins disclosed herein contain additional mutations within the repeating antigenic unit, and positions where additional substitutions can be made include positions 3, 5, and 8.

[0161] In some embodiments, at least one third amino acid of an antigenic unit may be replaced with a polar or positively charged amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 third amino acids of an antigenic unit may be replaced with a polar or positively charged amino acid. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all third amino acids of an antigenic unit may be replaced as described above.

[0162] In some embodiments, two or more third amino acids of an antigenic unit may be replaced with polar or positively charged amino acids. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 third amino acids of an antigenic unit may be replaced with polar or positively charged amino acids. In some embodiments, more than 50%, 60%, 70%, 80%, 90% or all of the third amino acids of an antigenic unit may be replaced as described above.

[0163] In some embodiments, one third amino acid of an antigenic unit may be replaced with a polar or positively charged amino acid. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 third amino acids of an antigenic unit may be replaced with a polar or positively charged amino acid. In some embodiments, 50%, 60%, 70%, 80%, 90% or all of the third amino acids of an antigenic unit may be replaced as described above.

[0164] In some embodiments, at least one fifth amino acid of an antigenic unit may be replaced with a hydrophobic amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 fifth amino acids of an antigenic unit may be replaced with a hydrophobic amino acid. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all fifth amino acids of an antigenic unit may be replaced as described above.

[0165] In some embodiments, two or more fifth amino acids of an antigenic unit may be replaced with a hydrophobic amino acid. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 fifth amino acids of an antigenic unit may be replaced with a hydrophobic amino acid. In some embodiments, more than 50%, 60%, 70%, 80%, 90% or all fifth amino acids of an antigenic unit may be replaced as described above.

[0166] In some embodiments, one fifth amino acid of an antigenic unit may be replaced with a hydrophobic amino acid. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 fifth amino acids of an antigenic unit may be replaced with a hydrophobic amino acid. In some embodiments, 50%, 60%, 70%, 80%, 90% or all fifth amino acids of an antigenic unit may be replaced as described above.

[0167] In some embodiments, at least one eighth amino acid of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 eighth amino acids of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some embodiments, at least 50%, 60%, 70%, 80%, 90% or all eighth amino acids of an antigenic unit may be replaced as described above.

[0168] In some aspects, two or more eighth amino acids of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some aspects, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or more than 30 eighth amino acids of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some aspects, more than 50%, 60%, 70%, 80%, 90% or all eighth amino acids of an antigenic unit may be replaced as described herein.

[0169] In some embodiments, one eighth amino acid of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 eighth amino acids of an antigenic unit may be replaced with a small amino acid or an aliphatic amino acid. In some embodiments, 50%, 60%, 70%, 80%, 90% or all eighth amino acids of an antigenic unit may be replaced as described above.

[0170] In some embodiments, the de-epitope-modified HMW glutenins disclosed herein having mutations at positions 1 and 9 further comprise at least two additional substitution mutations at any of positions 3, 5, and 8 of the repeating antigenic unit. In some embodiments, the de-epitope-modified HMW glutenins having mutations at positions 1 and 9 further comprise at least two additional substitution mutations at any of positions 3, 5, and 8, where the substitution at position 3 is a polar or positively charged amino acid; or the substitution at position 5 is a hydrophobic amino acid; or the substitution at position 8 is to a small or aliphatic amino acid; or any combination thereof. In some embodiments, the de-epitope-modified HMW glutenins having mutations at positions 3, 5, and 8 further comprise at least two additional substitution mutations at any of positions 3, 5, and 8, where the substitution at position 3 is arginine and the substitution at position 5 is leucine.

[0171] In some embodiments, the de-epitope-modified HMW glutenins disclosed herein with mutations at positions 1 and 9 comprise three additional substitution mutations at positions 3, 5, and 8 of the repeating antigenic unit. In some embodiments, the de-epitope-modified HMW glutenins with mutations at positions 1 and 9 comprise three additional substitution mutations at positions 3, 5, and 8, where the substitution at position 3 is arginine; or the substitution at position 5 is leucine; or the substitution at position 8 is to a small amino acid or an aliphatic amino acid; or any combination thereof. In some embodiments, the de-epitope-modified HMW glutenins comprising mutations at positions 1 and 9 comprise at least three additional substitution mutations at positions 3, 5, and 8, where the substitution at position 3 is arginine and the substitution at position 5 is leucine.

[0172] In some embodiments, the de-epitope-denatured HMW glutenin comprises a substitution mutation at position 9 of the repeat antigenic unit, including replacing the amino acid residue at position 9 with arginine, histidine, threonine, or glutamic acid, or a combination thereof if two or more repeat antigenic units are mutated. In some embodiments, the de-epitope-denatured HMW glutenin comprises a substitution mutation at position 1 of the repeat antigenic unit, including replacing the amino acid residue at position 1 with histidine, proline, serine, alanine, lysine, or glutamic acid, or a combination thereof if two or more repeat antigenic units are mutated.

[0173] In some embodiments, the amino acid sequence of the epitope-depleted HMW glutenin comprises any of the sequences set forth in SEQ ID NOs: 52, 102-107, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, 155-168, and 170-172. In some embodiments, the amino acid sequence of the epitope-depleted HMW glutenin comprising a mutation in a T-cell epitope comprises any of the sequences set forth in SEQ ID NOs: 52, 102-107, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, 155-168, and 170-172. In some embodiments, the amino acid sequence of the epitope-depleted HMW glutenin comprising a deletion of a T cell epitope comprises any of the sequences set forth in SEQ ID NOs: 52, 102-107, 167-168, and 170-172. In some embodiments, the amino acid sequence of the epitope-depleted HMW glutenin comprising a substitution mutation within a T cell epitope comprises any of the sequences set forth in SEQ ID NOs: 52, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, and 155-166.

[0174] In some embodiments, the amino acid sequence of the epitope-depleted HMW glutenin comprising a mutation of the repeating antigenic unit or a variant thereof comprises any of the sequences set forth in SEQ ID NOs: 52, 102-107, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, 155-168, and 170-172. In some embodiments, the amino acid sequence of the epitope-depleted HMW glutenin comprising a deletion of the repeating antigenic unit or a variant thereof comprises any of the sequences set forth in SEQ ID NOs: 52, 102-107, 167-168, and 170-172. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprising substitution mutations within the repeating antigenic unit or variations thereof comprises any of the sequences set forth in SEQ ID NOs: 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, and 155-166.

[0175] In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprising the substitution mutation comprises the sequence set forth in any of SEQ ID NOs: 38, 40-42, or 108-125. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in any of SEQ ID NOs: 38, 40, or 41. In certain embodiments, the de-epitopeed high molecular weight glutenin comprises at least one of the amino acid sequences set forth in SEQ ID NOs: 108-119. In certain embodiments, the de-epitopeed high molecular weight glutenin comprises at least one of the amino acid sequences set forth in SEQ ID NOs: 109, 111, 112, 115, 116, 117, 118, or 119. In certain embodiments, the de-epitopeed high molecular weight glutenin comprises at least one of the amino acid sequences set forth in SEQ ID NOs: 109, 111, 115, 116, 118, or 119. In certain embodiments, the de-epitopeed high molecular weight glutenin comprises at least one of the amino acid sequences set forth in SEQ ID NOs: 109, 111, or 119. In certain embodiments, the amino acid sequence of the de-epitopeed HMW glutenin in which all of the repeating units have been replaced is set forth in SEQ ID NOs: 126-142, 148-151, or 155-166. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprising a substitution mutation comprises a sequence set forth in any of SEQ ID NOs: 126-142, 148-151, or 155-166. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprising a deletion mutation comprises a sequence set forth in any of SEQ ID NOs: 52, 102-107, 167-168, or 170-172.

[0176] In some embodiments, the mutated antigenic unit comprises a sequence set forth in any of 52, 109-112, 114-116, or 118-119.

[0177] Non-limiting examples of mutated 15-mer peptides comprising antigenic units are provided in Figure 2, where positions 1 and 9 are mutated for each mutant antigenic unit shown.

[0178] Those skilled in the art will appreciate that de-epitope HMW glutenin containing mutated repeating antigenic units may, in some embodiments, be characterized by mutated repeating antigenic units that comprise 9-mer to 15-mer peptides or that are deletions of repeating antigenic units. In some embodiments, de-epitope HMW glutenin containing mutated repeating antigenic units may be characterized by de-epitope HMW glutenin partial sequences. Table 1 below shows de-epitope HMW glutenin partial amino sequences and the corresponding mutated repeating antigenic units or deletions thereof contained within these de-epitope HMW glutenin partial amino sequences.

[0179] [Table 1]

[0180] In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 38. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 40. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 41. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 42. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 51. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 52. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 53. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 54. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 55. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 56. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 102. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 103. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 104. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 105. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 106. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 107. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 108. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 109. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 110. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 111.In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 112. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 113. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 114. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 115. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 116. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 117. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 118. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 119. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 120. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 121. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 122. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 123. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 124. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 125. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 126. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 127. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 128. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 129. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 130. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 131.In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 132. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 133. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 134. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 135. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 136. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 137. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 138. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 140. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 141. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 142. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 143. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 144. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 145. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 146. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 147. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 148. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 149. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 150. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 151. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 155.In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 156. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 157. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 158. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 159. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 160. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 161. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 162. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 163. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 164. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 165. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 166. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 167. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 168. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 169. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 170. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 171. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 172. In some embodiments, the amino acid sequence of the de-epitopeed HMW glutenin comprises the sequence set forth in SEQ ID NO: 174.

[0181] Those skilled in the art will appreciate that the de-epitopeed HMW glutenins disclosed herein can comprise different combinations of the sequences disclosed above, e.g., different combinations of mutated repeating antigenic units. Thus, in some embodiments, for example, a single de-epitopeed high molecular weight glutenin can comprise a particular combination of SEQ ID NOs: 38, 40-42, and 108-119, and / or various copy numbers of any one of the sequences disclosed above.

[0182] In other embodiments, each of the nine amino acid repeating antigenic units in the modified HMW glutenin is replaced with a mutated antigenic unit containing the same mutation, which may be a substitution mutation within the antigenic unit or a deletion mutation of the antigenic unit.

[0183] According to some embodiments, the depitopied HMW glutenin does not comprise any of the sequences set forth in SEQ ID NOs: 57-69.

[0184] In some aspects, the mutations present in the depitopened HMW glutenins described herein do not adversely affect the functionality of the polypeptide (e.g., in the case of modified wheat HMW glutenins, the mutations do not affect the ability of the wheat polypeptide to produce dough with elastic properties).

[0185] In one embodiment, the term "mutating" can encompass expressing a recombinant polypeptide having a mutation relative to a wild-type (WT) protein, e.g., WT HMW glutenin. In some embodiments, the depitope-modified HMW glutenin polypeptides disclosed herein are recombinant polypeptides.

[0186] In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain antigenic units that bind to MHC class DQ2 or DQ8 with an IC50 of less than 30 μM. In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain repeat motifs that bind to MHC class DQ2 or DQ8 with an IC50 of less than 30 μM. In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain CD-associated epitopes that bind to MHC class DQ2 or DQ8 with an IC50 of less than 30 μM. In some aspects, peptides derived from the de-epitope-modified HMW glutenins disclosed herein do not bind to MHC class DQ2 or DQ8 with an IC50 of less than 30 μM.

[0187] In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain antigenic units that bind to MHC class DQ2 or DQ8 with an IC50 of less than 25 μM. In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain repeat motifs that bind to MHC class DQ2 or DQ8 with an IC50 of less than 25 μM. In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain CD-associated epitopes that bind to MHC class DQ2 or DQ8 with an IC50 of less than 25 μM. In some aspects, peptides derived from the de-epitope-modified HMW glutenins disclosed herein do not bind to MHC class DQ2 or DQ8 with an IC50 of less than 25 μM.

[0188] In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain antigenic units that bind to MHC class DQ2 or DQ8 with an IC50 of less than 20 μM. In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain repeat motifs that bind to MHC class DQ2 or DQ8 with an IC50 of less than 20 μM. In some aspects, the de-epitope-modified HMW glutenins disclosed herein do not contain CD-associated epitopes that bind to MHC class DQ2 or DQ8 with an IC50 of less than 20 μM. In some aspects, peptides derived from the de-epitope-modified HMW glutenins disclosed herein do not bind to MHC class DQ2 or DQ8 with an IC50 of less than 20 μM.

[0189] Nucleotides, Vectors, and Host Cells Disclosed herein are isolated polynucleotides encoding any of the above-described depitopied HMW glutenin polypeptides. Such polynucleotides can be used to express the above-described depitopied HMW glutenin polypeptides in a host cell (e.g., a bacterial, plant, yeast, or mammalian cell host).

[0190] In some aspects, disclosed herein are isolated polynucleotides encoding depitope-modified HMW glutenins.

[0191] As used herein, terms such as "nucleotide," "nucleotide sequence," "polynucleotide," "polynucleotide sequence," or "nucleic acid molecule" can encompass DNA molecules and RNA molecules or modified RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded. In some embodiments, the nucleotides comprise modified nucleotides. In some embodiments, the nucleotides comprise mRNA. In some embodiments, the nucleotides comprise modified mRNA. In some embodiments, the nucleotides comprise modified mRNA, and the modified mRNA comprises a 5'-capped mRNA. In some embodiments, the modified mRNA comprises a molecule in which some of the nucleosides are replaced with either naturally occurring modified nucleosides or synthetic nucleosides. In some embodiments, the modified nucleotides comprise modified mRNA comprising a 5'-capped mRNA, and some of the nucleosides are replaced with either naturally occurring modified nucleosides or synthetic nucleosides.

[0192] Those skilled in the art will understand that the terms "polynucleotide," "nucleic acid sequence," "nucleic acid," and variations thereof can be generic to encompass polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose), any other type of polynucleotide that is an N-glycoside of a purine or pyrimidine base, and other polymers containing a non-nucleotide backbone, provided that the polymer contains nucleobases in a configuration that allows for base pairing and base stacking, as found in DNA and RNA. Thus, these terms include known types of nucleic acid sequence modifications, such as substitution of one or more analogs of naturally occurring nucleotides, and internucleotide modifications.

[0193] In some embodiments, the isolated polynucleotide encoding an HMW glutenin comprises a nucleotide sequence that is essentially free from other genomic nucleotide sequences that naturally flank the nucleic acid in genomic DNA.

[0194] In some aspects, disclosed herein are nucleotide or nucleic acid sequences that encode any of the HMW glutenin molecules disclosed herein.

[0195] Methods for introducing nucleic acid changes into a gene of interest are well known in the art [see, e.g., Menke D. Genesis (2013) 51:-618; Capecchi, Science (1989) 244:1288-1292; Santiago et al. Proc Natl Acad Sci USA (2008) 105: 5809-5814; International Patent Application Nos. WO 2014085593, WO 2009071334 and WO 2011146121; U.S. Patent Nos. 8771945, 8586526, 6774279 and UP Patent Application Publication Nos. 20030232410, 20050026157, and U.S. Patent Application Publication No. 20060014264; the entire contents of which are incorporated by reference.] Genome editing includes targeted homologous recombination, site-specific recombinase, PB transposase and engineered nuclease. Agents for introducing nucleic acid changes into target genes can be designed by publicly available sources or commercially available from Transposagen, Addgene and Sangamo Biosciences. In some embodiments, generating changes in the sequence of a gene can be achieved by screening existing plant sequences for existing variants of the desired sequence. This existing sequence can then be introduced into the genome of the target genome by breeding or gene editing. In other embodiments, the desired mutation is introduced by introducing random mutagenesis, followed by screening for variants that have generated the desired mutation, and then breeding.

[0196] Below are descriptions of various exemplary methods used to introduce nucleic acid changes into a gene of interest, and agents for carrying them out, that can be used in accordance with specific embodiments disclosed herein.

[0197] Genome editing using engineered endonucleases—This approach refers to a reverse genetics method that uses artificially engineered nucleases to cleave and create specific double-strand breaks at desired locations in the genome, which are then repaired by cell-intrinsic processes such as homology-directed repair (HDS) and non-homologous end joining (NHEJ). While NHEJ directly joins DNA ends at double-strand breaks, HDR utilizes homologous sequences as templates to regenerate missing DNA sequences at the break points. To introduce specific nucleotide modifications into genomic DNA, a DNA repair template containing the desired sequence must be present during HDR. Genome editing cannot be performed using traditional restriction endonucleases because most restriction enzymes recognize a small number of base pairs on DNA as their targets, and the recognized base pair combinations are likely to be found at many locations throughout the genome, resulting in multiple breaks that are not restricted to the desired location. To overcome this challenge and create site-specific single- or double-strand breaks, several different classes of nucleases have been discovered and engineered. These include meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR / Cas systems.

[0198] Meganucleases—Meganucleases are generally classified into four families: the LAGLIDADG (SEQ ID NO: 36) family, the GIY-YIG (SEQ ID NO: 70) family, the His-Cys box family, and the HNH family. These families are characterized by structural motifs that affect catalytic activity and recognition sequences. For example, members of the LAGLIDADG (SEQ ID NO: 36) family are characterized by having either one or two copies of the conserved LAGLIDADG (SEQ ID NO: 36) motif. The four families of meganucleases are widely separated from each other in terms of conserved structural elements and, as a result, DNA recognition sequence specificity and catalytic activity. Meganucleases are generally found in microbial species and have the unique property of having very long recognition sequences (more than 14 bp), which naturally make them highly specific for cleavage at desired locations. This can be utilized to create site-specific double-strand breaks in genome editing. Those skilled in the art can use these naturally occurring meganucleases, but the number of such naturally occurring meganucleases is limited. To overcome this challenge, mutagenesis and high-throughput screening methods have been used to generate meganuclease variants that recognize unique sequences. For example, various meganucleases have been fused to generate hybrid enzymes that recognize new sequences. Alternatively, DNA-interacting amino acids of meganucleases can be altered to design sequence-specific meganucleases (see, e.g., U.S. Pat. No. 8,021,867). Meganucleases can be designed using, for example, the methods described in Certo, MT et al. Nature Methods (2012) 9:073-975; U.S. Patent Nos. 8,304,222; 8,021,867; 8,119,381; 8,124,369; 8,129,134; 8,133,697; 8,143,015; 8,143,016; 8,148,098; or 8,163,514, the entire contents of each of which are incorporated herein by reference.Alternatively, meganucleases with site-specific cleavage characteristics can be obtained using commercially available technologies, such as Precision Biosciences' Directed Nuclease Editor™ genome editing technology.

[0199] ZFN- and TALEN-Engineered Two different classes of nucleases, zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), have both proven effective in generating targeted double-strand breaks ( Christian et al., 2010 ; Kim et al., 1996 ; Li et al., 2011 ; Mahfouz et al., 2011 ; Miller et al., 2010 ).

[0200] Essentially, ZFN and TALEN restriction endonuclease technologies utilize a nonspecific DNA-cleaving enzyme linked to a specific DNA-binding domain (either a series of zinc finger domains or TALE repeats, respectively). Typically, a restriction enzyme is selected in which the DNA recognition site and cleavage site are separated from each other. The cleavage site is then ligated to the DNA-binding domain, resulting in an endonuclease with extremely high specificity for the desired sequence. An exemplary restriction enzyme with such properties is Fokl. Furthermore, Fokl has the advantage of requiring dimerization to have nuclease activity, meaning that specificity is dramatically increased because each nuclease partner recognizes a unique DNA sequence. To enhance this effect, Fokl nucleases have been engineered that can function only as heterodimers and have increased catalytic activity. Heterodimeric nucleases avoid the potential for undesired homodimer activity, thus increasing the specificity of double-strand cleavage.

[0201] Thus, for example, to target specific sites, ZFNs and TALENs are constructed as nuclease pairs, with each member of the pair designed to bind to adjacent sequences at the target site. Upon transient expression in cells, the nucleases bind to their target site, and the FokI domains heterodimerize to generate double-strand breaks. Repair of these double-strand breaks through the non-homologous end joining (NHEJ) pathway most often results in small deletions or small sequence insertions. Because each repair performed by NHEJ is unique, the use of a single nuclease pair can generate a series of alleles with a variety of different deletions at the target site. Deletions typically range in length from a few base pairs to several hundred base pairs, but larger deletions have been successfully generated in cell culture by simultaneously using two pairs of nucleases (Carlson et al., 2012; Lee et al., 2010). Furthermore, when a fragment of DNA with homology to the target region is introduced in conjunction with a nuclease pair, the double-strand break can be repaired via homology-directed repair to generate specific modifications ( Li et al., 2011 ; Miller et al., 2010 ; Urnov et al., 2005 ).

[0202] While the nuclease moieties of both ZFNs and TALENs share similar properties, the difference between these engineered nucleases lies in their DNA recognition peptides. ZFNs rely on Cys2-His2 zinc fingers, while TALENs rely on TALEs. Both of these DNA recognition peptide domains share the characteristic of naturally occurring combinations in proteins. Cys2-His2 zinc fingers are typically found in repeats spaced 3 bp apart and in diverse combinations in various nucleic acid-interacting proteins. TALEs, on the other hand, are found in repeats with a one-to-one recognition ratio between the amino acid and the recognized nucleotide pair. Because both zinc fingers and TALEs occur in a repetitive pattern, different combinations can be experimented with to create a wide variety of sequence specificities. Approaches for generating site-specific zinc finger endonucleases include, for example, modular assembly (zinc fingers correlating with triplet sequences are linked in a line to cover the required sequence), OPEN (low stringency selection of peptide domains against triplet nucleotides, followed by high stringency selection of peptide combinations against the final target in a bacterial system), and bacterial one-hybrid screening of zinc finger libraries. ZFNs can also be designed and commercially available, for example, from Sangamo Biosciences™ (Richmond, CA).

[0203] Methods for designing and obtaining TALENs are described, for example, in Reyon et al. Nature Biotechnology 2012 May;30(5):460-5; Miller et al. Nat Biotechnol. (2011) 29:143-148; Cermak et al. Nucleic Acids Research (2011) 39(12):e82 and Zhang et al. Nature Biotechnology (2011) 29(2):149-53. A recently developed web-based program called Mojo Hand was introduced by Mayo Clinic to design TAL and TALEN constructs for genome editing applications (accessible through www(dot)talendesign(dot)org). TALENs can also be designed and commercially obtained, for example, from Sangamo Biosciences™ (Richmond, CA).

[0204] CRISPR-Cas systems—Many bacteria and archaea contain endogenous RNA-based adaptive immune systems capable of degrading the nucleic acids of invading phages and plasmids. These systems consist of clustered regularly interspaced short palindromic repeats (CRISPR) genes, which produce the RNA component, and CRISPR-associated (Cas) genes, which encode the protein component. CRISPR RNA (crRNA) contains short stretches of homology to specific viruses and plasmids and acts as a guide, directing Cas nucleases to degrade complementary nucleic acids in the corresponding pathogen. Studies of the type II CRISPR / Cas system of Streptococcus pyogenes showed that three components—the Cas9 nuclease, the crRNA containing 20 base pairs of homology to the target sequence, and the trans-activating crRNA (tracrRNA)—form an RNA / protein complex that, together, is sufficient for sequence-specific nuclease activity (Jinek et al., Science (2012) 337:816-821). It has further been demonstrated that synthetic chimeric guide RNAs (gRNAs) composed of a fusion between a crRNA and a tracrRNA can direct Cas9 to cleave DNA targets complementary to the crRNA in vitro. It has also been demonstrated that transient expression of Cas9 in conjunction with synthetic gRNAs can be used to generate targeted double-stranded brakes in a variety of different species (Cho et al., 2013; Cong et al., 2013; DiCarlo et al., 2013; Hwang et al., 2013a, b; Jinek et al., 2013; Mali et al., 2013).

[0205] The CRIPSR / Cas system for genome editing contains two distinct components: a gRNA and an endonuclease, such as Cas9.

[0206] A gRNA is typically a 20-nucleotide sequence that encodes a combination of a target homologous sequence (crRNA) and an endogenous bacterial RNA that ligates the crRNA to the Cas9 nuclease (tracrRNA) to form a single chimeric transcript. The gRNA / Cas9 complex is recruited to the target sequence by base pairing between the gRNA sequence and complementary genomic DNA. For successful Cas9 binding, the genomic target sequence must also contain the correct protospacer adjacent motif (PAM) sequence immediately following the target sequence. Binding of the gRNA / Cas9 complex localizes Cas9 to the genomic target sequence so that it can cleave both strands of DNA, creating a double-stranded break. Similar to ZFNs and TALENs, the double-stranded brake produced by CRISPR / Cas can undergo homologous recombination or NHEJ.

[0207] The Cas9 nuclease has two functional domains: RuvC and HNH, each of which cleaves a different DNA strand. When both of these domains are active, Cas9 creates a double-strand break in genomic DNA.

[0208] A key advantage of CRISPR / Cas is that the high efficiency of this system, coupled with the ability to easily generate synthetic gRNAs, allows for the simultaneous targeting of multiple genes. Furthermore, the majority of cells carrying mutations will display biallelic mutations in the targeted genes.

[0209] However, apparent flexibility in the base-pairing interactions between the gRNA sequence and the genomic DNA target sequence allows for an imperfect match to the target sequence to be cleaved by Cas9.

[0210] Modified versions of the Cas9 enzyme containing a single inactive catalytic domain (either RuvC or HNH) are called "nickases." With only one active nuclease domain, Cas9 nickases cleave only one strand of the target DNA, creating a single-strand break or "nick." Single-strand breaks or nicks are typically rapidly repaired through the HDR pathway, using the intact complementary DNA strand as a template. However, two adjacent, opposite-strand nicks introduced by Cas9 nickases are often treated as double-strand breaks in what are often referred to as "double-nick" CRISPR systems. Double nicks can be repaired by either NHEJ or HDR, depending on the desired effect on the gene target. Therefore, if specificity and reduced off-target effects are important, using Cas9 nickases to create double nicks by designing two gRNAs whose target sequences are adjacent to and on opposite strands of the genomic DNA will reduce off-target effects because either gRNA alone will create a nick that does not alter the genomic DNA.

[0211] A modified version of the Cas9 enzyme containing two inactive catalytic domains (dead Cas9, or dCas9) lacks nuclease activity but can still bind to DNA based on gRNA specificity. By fusing the inactive enzyme to known regulatory domains, dCas9 can be used as a platform for DNA transcription regulators to activate or repress gene expression. For example, binding of dCas9 alone to a target sequence in genomic DNA can disrupt gene transcription.

[0212] There are several publicly available tools available to assist in the selection and / or design of target sequences, such as Target Finder from the Feng Zhang lab, Target Finder (E-CRISP) from the Michael Boutros lab, RGEN Tools:Cas-OFFinder, CasFinder: a flexible algorithm for identifying specific Cas9 targets in genomes, and CRISPR Optimal Target Finder, as well as lists of bioinformatically determined unique gRNAs for different genes in different species.

[0213] To use the CRISPR system, both the gRNA and Cas9 must be expressed in the target cell. The insertion vector can contain both cassettes on a single plasmid, or the cassettes are expressed from two separate plasmids. CRISPR plasmids, such as the px330 plasmid from Addgene, are commercially available.

[0214] "Hit-and-run" or "in-out" recombination involves a two-step recombination procedure. In the first step, an insertion vector containing a dual positive / negative selection marker cassette is used to introduce the desired sequence change. The insertion vector contains a single contiguous region of homology to the targeted locus and is modified to carry the desired mutation. This targeting construct is linearized with a restriction enzyme at one site within the region of homology, electroporated into cells, and positive selection is performed to isolate homologous recombinants. These homologous recombinants contain local duplications separated by intervening vector sequences containing the selection cassette. In the second step, targeted clones are subjected to negative selection to identify cells that have lost the selection cassette via intrachromosomal recombination between the duplicated sequences. The local recombination event removes the duplication, and depending on the recombination site, the allele either retains the introduced mutation or reverts to wild-type. The end result is the introduction of the desired modification without retaining any exogenous sequences.

[0215] The "double replacement" or "tag and exchange" strategy involves a two-step selection procedure similar to the hit-and-run approach, but requires the use of two different targeting constructs. In the first step, a standard targeting vector with 3' and 5' homology arms is used to insert a double positive / negative selectable cassette near the position where the mutation is to be introduced. After electroporation and positive selection, homologously targeted clones are identified. Next, a second targeting vector containing the region of homology with the desired mutation is electroporated into the targeted clone, and negative selection is applied to remove the selection cassette and introduce the mutation. The final allele contains the desired mutation while eliminating the undesired exogenous sequence.

[0216] Cre recombinase from the site-specific recombinase-P1 bacteriophage and Flp recombinase from the yeast Saccharomyces cerevisiae are site-specific DNA recombinases that recognize unique 34-base pair DNA sequences (termed "Lox" and "FRT," respectively). Sequences flanking either Lox or FRT sites can be easily removed via site-specific recombination upon expression of Cre or Flp recombinase, respectively. For example, Lox sequences consist of an asymmetric 8-base pair spacer region flanked by 13-base pair inverted repeat sequences. Cre binds to the 13-base pair inverted repeat sequences and rejoins the 34-base pair Lox DNA sequence by catalyzing strand cleavage and religation within the spacer region. The staggered DNA breaks made by Cre within the spacer region are separated by 6 base pairs, providing an overlap region that acts as a homology sensor to ensure that only recombination sites with the same overlapping region rejoin.

[0217] Essentially, site-specific recombinase systems provide a means for removing the selection cassette after homologous recombination. This system also allows for the generation of conditional modified alleles that can be inactivated or activated in a transient or tissue-specific manner. Notably, Cre and Flp recombinases leave a 34-base pair Lox or FRT "scar." The remaining Lox or FRT sites are typically left in the introns or 3'UTR of the modified locus, and current evidence suggests that these sites usually do not significantly interfere with gene function.

[0218] Thus, Cre / Lox and Flp / FRT recombination involve the introduction of a targeting vector with 3' and 5' homology arms containing the desired mutation, two Lox or FRT sequences, and a selectable cassette typically located between the two Lox or FRT sequences. Positive selection is applied to identify homologous recombinants containing the targeted mutation. Transient expression of Cre or Flp, coupled with negative selection, results in excision of the selection cassette and selects for cells in which the cassette has been lost. The final targeted allele contains a Lox or FRT scar of the exogenous sequence.

[0219] Transposase - As used herein, the term "transposase" refers to an enzyme that binds to the ends of a transposon and catalyzes the movement of the transposon to another part of the genome.

[0220] As used herein, the term "transposon" refers to a mobile genetic element containing a nucleotide sequence that can move to different locations within the genome of a single cell. In this process, transposons can cause mutations and / or change the amount of DNA in the genome of the cell.

[0221] Several transposon systems capable of transposing within cells, even vertebrates, have been isolated or engineered, such as Sleeping Beauty [Izsvak and Ivics Molecular Therapy (2004) 9, 147–156], piggyBac [Wilson et al. Molecular Therapy (2007) 15, 139–145], Tol2 [Kawakami et al. PNAS (2000) 97(21):11403–11408], or Frog Prince [Miskey et al. Nucleic Acids Res. Dec 1, (2003) 31(23):6873–6881]. Generally, DNA transposons transpose from one DNA site to another in a simple cut-and-paste fashion. Each of these elements has its own advantages; for example, Sleeping Beauty is particularly useful in region-specific mutagenesis, while Tol2 has the highest tendency to integrate into expressed genes. Hyperactive systems are available for Sleeping Beauty and piggyBac. Most importantly, these transposons have distinct target site preferences and can therefore introduce sequence changes into overlapping but distinct sets of genes. Therefore, the use of two or more elements is particularly preferred to achieve the best possible gene coverage. Because the basic mechanism is shared between different transposases, piggyBac (PB) is used as an example.

[0222] PB is a 2.5 kb insect transposon originally isolated from the nettle looper moth (Trichoplusia ni). The PB transposon consists of asymmetric terminal repeats flanked by a transposase, PBase. PBase recognizes the terminal repeats and directs transposition via a "cut-and-paste"-based mechanism, preferentially transposing into the host genome at the tetranucleotide sequence TTAA. Upon insertion, the TTAA target site is duplicated so that the PB transposon is flanked by this tetranucleotide sequence. Upon mobilization, PB typically precisely excises itself to reestablish a single TTAA site, thereby returning the host sequence to its pretransposon state. After excision, PB can either transpose to a new location or be permanently lost from the genome.

[0223] Typically, transposase systems offer an alternative means for removing a selection cassette after homologous recombination, much like the use of Cre / Lox or Flp / FRT. Thus, for example, the PB transposase system involves the introduction of a targeting vector with 3' and 5' homology arms containing the desired mutation, two PB terminal repeats at the site of the endogenous TTAA sequence, and a selection cassette positioned between the PB terminal repeats. Positive selection is applied to identify homologous recombinants containing the targeted mutation. Transient expression of PBase, combined with negative selection, results in excision of the selection cassette, selecting for cells in which the cassette has been lost. The final targeted allele contains the introduced mutation without the exogenous sequence.

[0224] For PB to be useful for introducing sequence changes, there must be a naturally occurring TTAA site relatively close to the location where the particular mutation is to be inserted.

[0225] Genome editing using a recombinant adeno-associated virus (rAAV) platform—This genome editing platform is based on rAAV vectors, which allow for the insertion, deletion, or replacement of DNA sequences within the genome of living mammalian cells. The rAAV genome is a single-stranded deoxyribonucleic acid (ssDNA) molecule, approximately 4.7 kb in length, either positive-sense or negative-sense. These single-stranded DNA viral vectors have the unique property of having high transduction rates and stimulating endogenous homologous recombination in the absence of double-stranded DNA breaks within the genome. Those skilled in the art can design rAAV vectors to target desired genomic loci and perform both large-scale and / or subtle endogenous genetic changes within cells. rAAV genome editing has the advantage of targeting a single allele and not resulting in any off-target genomic changes. rAAV genome editing technology is commercially available, for example, as the rAAV GENESIS™ system from Horizon™ (Cambridge, UK).

[0226] Methods for validating and detecting sequence variations are well known in the art and include, but are not limited to, DNA sequencing, electrophoresis, enzyme-based mismatch detection assays and hybridization assays such as PCR, RT-PCR, RNase protection, in situ hybridization, primer extension, Southern blot, Northern blot and dot blot analysis.

[0227] Sequence variations in specific genes can also be determined at the protein level using, for example, chromatography, electrophoresis, immunodetection assays such as ELISA and Western blot analysis, and immunohistochemistry.

[0228] Furthermore, one skilled in the art can readily design knock-in / knock-out constructs containing positive and / or negative selection markers for efficient selection of transformed cells that have undergone a homologous recombination event with the construct. Positive selection provides a means of enriching a population of clones that have integrated foreign DNA. Non-limiting examples of such positive markers include markers that confer antibiotic resistance, such as glutamine synthetase, dihydrofolate reductase (DHFR), neomycin, hygromycin, puromycin, and blasticidin S resistance cassettes. Negative selection markers are necessary to select against random integration and / or excision of the marker sequence (e.g., the positive marker). Non-limiting examples of such negative markers include herpes simplex thymidine kinase (HSV-TK), which converts ganciclovir (GCV) into a cytotoxic nucleoside analog, hypoxanthine phosphoribosyltransferase (HPRT), and adenine phosphoribosyltransferase (ARPT).

[0229] In some aspects, disclosed herein are expression vectors comprising an isolated polynucleotide comprising any of the de-epitope-modified HMW glutenin modified proteins disclosed herein operably linked to a transcriptional regulatory sequence to allow expression of the de-epitope-modified HMW glutenin in a plant cell. In some aspects, disclosed herein are host cells comprising an expression vector comprising an isolated polynucleotide comprising any of the de-epitope-modified HMW glutenin modified proteins disclosed herein. In some aspects, the host cell comprises a plant cell. In some aspects, the plant cell comprises a wheat cell. In some aspects, the plant cell comprises a corn cell. In some aspects, the plant cell comprises a tobacco cell. In some aspects, the host cell comprises a yeast cell. In some aspects, the host cell comprises a bacterial cell. In some aspects, the host cell comprises a mammalian cell.

[0230] In some embodiments, the plant cells comprise de-epitope-modified HMW glutenin. In some embodiments, the plant cells comprise de-epitope-modified HMW glutenin, and the de-epitope-modified HMW glutenin is derived from the same species of plant as the plant cells. In some embodiments, the plant cells comprise de-epitope-modified HMW glutenin, and the de-epitope-modified HMW glutenin is derived from a different species of plant as the plant cells.

[0231] In some embodiments, plant cells comprise de-epitope-modified HMW glutenin. In some embodiments, bacterial cells comprise de-epitope-modified HMW glutenin. In some embodiments, yeast cells comprise de-epitope-modified HMW glutenin. In some embodiments, mammalian cells comprise de-epitope-modified HMW glutenin.

[0232] In some embodiments, the bacterial cell comprises a polynucleotide encoding the depitope-modified HMW glutenin. In some embodiments, the bacterial cell comprises a polynucleotide encoding the depitope-modified HMW glutenin. In some embodiments, the bacterial cell comprises a polynucleotide encoding the depitope-modified HMW glutenin. In some embodiments, the yeast cell comprises a polynucleotide encoding the depitope-modified HMW glutenin. In some embodiments, the mammalian cell comprises a polynucleotide encoding the depitope-modified HMW glutenin.

[0233] In some embodiments, the bacterial cell comprises an expression vector comprising a nucleotide encoding the depitope-modified HMW glutenin. In some embodiments, the bacterial cell comprises an expression vector comprising a polynucleotide encoding the depitope-modified HMW glutenin. In some embodiments, the yeast cell comprises an expression vector comprising a polynucleotide encoding the depitope-modified HMW glutenin. In some embodiments, the mammalian cell comprises an expression vector comprising a polynucleotide encoding the depitope-modified HMW glutenin.

[0234] As used herein, the term "vector" refers to a discrete element that is used to introduce heterologous nucleic acid into cells for either its expression or replication. Expression vectors include vectors capable of expressing nucleic acids that are operably linked to regulatory sequences, such as promoter regions, that are capable of affecting the expression of such nucleic acids. Thus, an expression vector can refer to a DNA or RNA construct, such as a plasmid, phage, recombinant virus, or other vector, that results in expression of a nucleic acid upon introduction into an appropriate host cell. Suitable expression vectors are well known to those of skill in the art and include those that are replicable in prokaryotic and / or eukaryotic cells, as well as those that remain episomal or those that integrate into the host cell genome.

[0235] In some aspects, disclosed herein are expression vectors comprising a nucleic acid construct encoding any of the HMW glutenin modified proteins disclosed herein.

[0236] As used herein, the term "recombinant host cell" (or simply "host cell") refers to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in successive generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

[0237] Commonly used expression systems for heterologous protein production include bacterial cells (e.g., E. coli), fungal cells (e.g., S. cerevisiae cells), plant cells (e.g., wheat, tobacco, corn), insect cells (lepidopteran cells), and mammalian cells (e.g., but not limited to, Chinese hamster ovary cells).

[0238] Expression of an exogenous polynucleotide of the invention in a host cell, such as, but not limited to, a plant cell, can be achieved by transforming one or more cells of the host with the exogenous polynucleotide.

[0239] In some aspects, disclosed herein are host cells comprising an expression vector carrying a nucleic acid construct encoding any of the HMW glutenin modified proteins disclosed herein. In one aspect, the cell or host cell is a prokaryotic cell or a eukaryotic cell. In one aspect, the eukaryotic cell is a yeast cell, an algae cell, a plant cell, or a mammalian cell. In some aspects, the plant cell comprises a wheat cell, a corn cell, or a tobacco cell.

[0240] A variety of methods can be used to introduce expression vectors of some embodiments of the present invention into cells. Such methods are generally described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory, New York (1989, 1992), Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989), Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Mich. (1995), Vega et al., Gene Targeting, CRC Press, Ann Arbor, Mich. (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths, Boston, Mass. (1988), and Gilboa et al. [Biotechniques 4(6):504-512, 1986] and include, for example, stable or transient transfection, lipofection, electroporation, and infection with recombinant viral vectors. See also US Pat. Nos. 5,464,764 and 5,487,992 for positive-negative selection methods.

[0241] Preferably, transformation is carried out by introducing into the host cell a nucleic acid construct comprising an exogenous polynucleotide encoding the depitopied HMW glutenin and at least one promoter capable of directing transcription of the exogenous polynucleotide in the host cell. Further details of suitable transformation techniques are provided herein below.

[0242] As used herein, the term "promoter" refers to a region of DNA upstream of the transcription start site of a gene where RNA polymerase binds and initiates transcription of RNA. A promoter controls where (e.g., which part of a plant, which organ in an animal, etc.) and / or when (e.g., at what stage or state of the life of an organism) a gene is expressed.

[0243] Any suitable promoter sequence can be used by the nucleic acid construct encoding the depitope-modified HMW glutenin. In some aspects, the promoter is a constitutive promoter, a tissue-specific promoter, or a plant-specific promoter, such as, but not limited to, a wheat promoter.

[0244] Suitable constitutive promoters include, for example, the CaMV 35S promoter (Odell et al., Nature, 313:810-812, 1985); maize Ubi 1 (Christensen et al., Plant Sol. Biol. 18:675-689, 1992); rice actin (McElroy et al., Plant Cell 2:163-171, 1990); rice glutelin (Qu, Le Qing et al. J Exp Bot 59:9, 2417-2424, 2008); pEMU (Last et al., Theor. Appl. Genet. 81:581-588, 1991); and Synthetic Super MAS (Ni et al., The Plant Journal 7:661-76, 1995). Other constitutive promoters include those in U.S. Patent Nos. 5,659,026; 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; and 5,608,142.

[0245] According to some embodiments, the promoter is a maize promoter (zein) as described in Joshi, J. Beslin et al., Physiology and Molecular Biology of Plants 21:35-42, 2015.

[0246] Suitable tissue-specific promoters include, but are not limited to, leaf-specific promoters such as those described by Yamamoto et al., Plant J. 12:255-265, 1997; Kwon et al., Plant Physiol. 105:357-67, 1994; Yamamoto et al., Plant Cell Physiol. 35:773-778, 1994; Gotor et al., Plant J. 3:509-18, 1993; Orozco et al., Plant Mol. Biol. 23:1129-1138, 1993; and Matsuoka et al., Proc. Natl. Acad. Sci. USA 90:9586-9590, 1993.

[0247] Suitable wheat-specific promoters include, but are not limited to, those described in Smirnova, OG and Kochetov, AVRuss J Genet Appl Res (2012) 2:434. www(dot)doi(dot)org / 10(dot)1134 / S2079059712060123.

[0248] In some embodiments, the nucleic acid construct encoding the depitope-enhanced HMW glutenin may further comprise an appropriate selection marker and / or origin of replication. In some embodiments, the nucleic acid construct utilized is a shuttle vector that can be propagated in E. coli (the construct comprises an appropriate selection marker and origin of replication) and simultaneously be compatible with propagation in cells. The construct comprising the polynucleotide encoding the depitope-enhanced HMW glutenin may be, for example, a plasmid, bacmid, phagemid, cosmid, phage, virus, or artificial chromosome.

[0249] The nucleic acid constructs disclosed herein can be used to stably or transiently transform plant cells. In stable transformation, the exogenous polynucleotides disclosed herein are integrated into the plant genome, thus representing a stable and heritable trait. In transient transformation, the exogenous polynucleotides are expressed by the transformed cells but are not integrated into the genome, thus representing a transient trait.

[0250] There are various methods for introducing foreign genes into both monocotyledonous and dicotyledonous plants (Potrykus, I., Annu. Rev. Plant. Physiol., Plant. Mol. Biol. (1991) 42:205-225; Shimamoto et al., Nature (1989) 338:274-276).

[0251] The principal methods for stable integration of exogenous DNA into plant genomic DNA include two main approaches: (i) Agrobacterium-mediated gene transfer: Klee et al. (1987) Annu. Rev. Plant Physiol. 38:467-486; Klee and Rogers, Cell Culture and Somatic Cell Genetics of Plants, Vol. 6, Molecular Biology of Plant Nuclear Genes, Schell, J. and Vasil, L.K. (eds.), Academic Publishers, San Diego, Calif. (1989) pp. 2-25; Gatenby, Plant Biotechnology, Kung, S. and Arntzen, C.J. (eds.), Butterworth Publishers, Boston, Mass. (1989) pp. 93-112.

[0252] (ii) Direct DNA uptake: Paszkowski et al., Cell Culture and Somatic Cell Genetics of Plants, Vol. 6, Molecular Biology of Plant Nuclear Genes, Schell, J. and Vasil, LK (eds.), Academic Publishers, San Diego, Calif. (1989) pp. 52-68; Direct uptake of DNA into protoplasts, Toriyama, K. et al. (1988) Bio / Technology 6:1072-1074. DNA uptake induced by brief electric shock of plant cells: Zhang et al., Plant Cell Rep. (1988) 7:379-384. Fromm et al. Nature (1986) 319:791-793. DNA injection into plant cells or tissues by particle bombardment; Klein et al. Bio / Technology (1988) 6:559-563; McCabe et al. Bio / Technology (1988) 6:923-926; Sanford, Physiol. Plant. (1990) 79:206-209; use of a micropipette system (1987) 75:30-36; Neuhaus and Spangenberg, Physiol. Plant. (1990) 79:213-217; glass fiber or silicon carbide whisker transformation of cell cultures, embryos, or callus tissue, U.S. Pat. No. 5,464,765, or by direct incubation of DNA with germinated pollen, DeWet et al., Experimental Manipulation of Ovule Tissue, Chapman, GP, Mantell, SH, and Daniels, W., eds., Longman, London, (1985) 197-209; and Ohta, Proc. Natl. Acad. Sci. USA (1986) 83:715-719.

[0253] The Agrobacterium system involves the use of a plasmid vector containing a predetermined DNA segment that is integrated into the plant genomic DNA. Methods for inoculating plant tissue vary depending on the plant species and the Agrobacterium delivery system. A widely used technique is the leaf disc procedure, which can be performed with any tissue explant, providing a good source for initiating whole plant differentiation. Horsch et al., Plant Molecular Biology Manual A5, Kluwer Academic Publishers, Dordrecht (1988), pp. 1-9. An adjunct technique uses the Agrobacterium delivery system in combination with vacuum infiltration. The Agrobacterium system is particularly viable for generating transgenic dicotyledonous plants.

[0254] There are various methods for direct DNA introduction into plant cells. In electroporation, protoplasts are briefly exposed to a strong electric field. In microinjection, DNA is mechanically injected directly into cells using a very small micropipette. In biolistic bombardment, DNA is adsorbed onto microprojectiles such as magnesium sulfate crystals or tungsten particles, and the microprojectiles are physically accelerated into cells or plant tissue.

[0255] After stable transformation, the plant is propagated. The most common method of plant propagation is by seed. However, regeneration by seed propagation has the disadvantage that there is a lack of uniformity in the crop due to heterozygosity, since seeds are produced by plants according to genetic differences governed by Mendelian laws. Essentially, each seed is genetically different and grows with unique traits. Therefore, it is preferable that transformed plants are produced so that the regenerated plants have the same traits and characteristics as the parent transgenic plant. Therefore, it is preferable that transformed plants are regenerated by micropropagation, which provides rapid and consistent regeneration of transformed plants.

[0256] Micropropagation is a method of growing new-generation plants from a single piece of tissue excised from a selected parent plant or cultivar. This method allows for the mass reproduction of plants with the desired tissue expressing the fusion protein. The new-generation plants produced are genetically identical to the original plant and possess all of the characteristics of the original plant. Micropropagation allows for the mass production of high-quality plant material in a short period of time and provides for the rapid propagation of selected cultivars while preserving the characteristics of the original transgenic or transformed plant. The advantages of cloning plants are the speed of plant propagation and the quality and uniformity of the plants produced.

[0257] Micropropagation is a multi-step procedure that requires changes in culture medium or growth conditions between steps. Thus, micropropagation involves four basic steps: step 1, initial tissue culture; step 2, tissue culture propagation; step 3, differentiation and plant formation; and step 4, greenhouse culture and hardening. During step 1, initial tissue culture, the tissue culture is established and certified contaminant-free. During step 2, the initial tissue culture is propagated until a sufficient number of tissue samples are produced to meet production goals. During step 3, the tissue samples grown in step 2 are divided and grown into individual plantlets. In step 4, the transformed plantlets are transferred to a greenhouse for hardening, where the plants' light tolerance is gradually increased so that they can grow in their natural environment.

[0258] Although stable transformation is presently preferred, transient transformation of leaf cells, meristematic cells, or whole plants is also envisioned by the present invention.

[0259] Transient transformation can be effected by any of the direct DNA transfer methods described above, or by viral infection using modified plant viruses.

[0260] Viruses that have been shown to be useful for transforming plant hosts include CaMV, TMV, and BV. Transformation of plants using plant viruses is described in U.S. Pat. No. 4,855,237 (BGV), European Patent Application Publication No. 67,553 (TMV), Japanese Patent Application Publication No. 63-14693 (TMV), European Patent Application Publication No. 194,809 (BV), European Patent Application Publication No. 278,667 (BV); and Gluzman, Y. et al., Communications in Molecular Biology: Viral Vectors, Cold Spring Harbor Laboratory, New York, pp. 172-189 (1988). Pseudovirus particles for use in expressing foreign DNA in many hosts, including plants, are described in International Publication No. WO 87 / 06261.

[0261] Preferably, the viruses disclosed herein are avirulent and therefore incapable of causing severe symptoms such as reduced growth rate, mosaicism, ring spot, leaf curl, yellowing, streaking, pox formation, tumor formation, and spot rot. Suitable avirulent viruses can be naturally occurring avirulent viruses or artificially attenuated viruses. Attenuation of viruses can be achieved by using methods well known in the art, including, but not limited to, sublethal heat, chemical treatment, or by directed mutagenesis techniques such as those described by Kurihara and Watanabe (Molecular Plant Pathology 4:259-269, 2003), Gal-on et al. (1992), Atreya et al. (1992), and Huet et al. (1994).

[0262] Suitable virus strains can be obtained from available sources, such as the American Type Culture Collection (ATCC), or by isolation from infected plants. Virus isolation from infected plant tissue can be performed by techniques well known in the art, such as those described in "Plant Virology Protocols: From Virus Isolation to Transgenic Resistance" (Methods in Molecular Biology (Humana Press), Vol. 81), edited by Foster and Tatlor, Humana Press, 1998. Briefly, infected plant tissues, preferably young leaves and petals, suspected of containing high concentrations of the appropriate virus are ground in a buffer solution (e.g., phosphate buffer) to produce a viral infected sap that can be used for subsequent inoculation. The construction of plant RNA viruses for the introduction and expression of non-viral exogenous polynucleotide sequences in plants has been demonstrated in the above references as well as by Dawson, WO et al., Virology (1989) 172:285-292; Takamatsu et al., EMBO J. (1987) 6:307-311; French et al., Science (1986) 231:1294-1297; and Takamatsu et al., FEBS Letters (1990) 269:73-76.

[0263] If the virus is a DNA virus, the virus itself can be appropriately modified. Alternatively, to facilitate the construction of the desired viral vector containing foreign DNA, the virus can first be cloned into a bacterial plasmid. The virus can then be excised from the plasmid. If the virus is a DNA virus, a bacterial replication origin can be attached to the viral DNA, which is then replicated by the bacterium. The transcription and translation of this DNA produces a coat protein that encapsidates the viral DNA. If the virus is an RNA virus, the virus is generally cloned as a cDNA and inserted into a plasmid. The plasmid is then used to create all of the constructs. The viral sequence in the plasmid is then transcribed, and the viral genes are translated to produce a coat protein that encapsidates the viral RNA, thereby producing an RNA virus.

[0264] The construction of plant RNA viruses for the introduction and expression in plants of non-viral exogenous polynucleotide sequences, such as those contained in the constructs disclosed herein, is demonstrated in the above references as well as in U.S. Pat. No. 5,316,931.

[0265] Techniques for inoculating plants with viruses can be found in Foster and Taylor, eds., "Plant Virology Protocols: From Virus Isolation to Transgenic Resistance (Methods in Molecular Biology (Humana Pr), Vol. 81)," Humana Press, 1998; Maramorosh and Koprowski, eds., "Methods in Virology," Vol. 7, Academic Press, New York, 1967-1984; Hill, SA, "Methods in Plant Virology," Blackwell, Oxford, 1984; Walkey, DGA, "Applied Plant Virology," Wiley, New York, 1985; and Kado and Agrawa, eds., "Principles and Techniques in Plant Virology," Van Nostrand-Reinhold, New York.

[0266] Mature plants produced from the transformed cells can then be cultured under conditions suitable for expression of the exogenous polynucleotide within the mature plant.

[0267] In one aspect, the plant host cell transfected with the expression construct does not naturally express gluten polypeptides (i.e., is derived from a non-gluten plant). Thus, in one aspect, the host cell is selected from the group consisting of amaranth, buckwheat, rice (brown, white, wild), maize, millet, quinoa, sorghum, Montina, Job's tears, and teff.

[0268] In another embodiment, the plant host cell transfected with the expression construct expresses wild-type gluten polypeptides. Such host cells include, but are not limited to, wheat varieties such as spelt, Kamut, faro, and durum wheat, bulgur, semolina, barley, rye, triticale, Triticum (wheat cultivars - Fielder, Spelling, Bobwhite, Cheyenne, Chinese Spring, and Mjolnir), and oats. It will be understood that the inventors further contemplate down-regulating the expression of wild-type gluten polypeptides in host cells that naturally express gluten polypeptides. Methods for down-regulating the expression of wild-type gluten polypeptides are known in the art and include, for example, the use of RNA silencing agents and DNA editing agents. Examples of RNA silencing agents include, but are not limited to, siRNA, miRNA, antisense molecules, DNAzymes, and RNAzymes.One method of down-regulating the expression of gluten polypeptide is described in Sanchez-Leon, Susana et al., "Low-gluten, Nontransgenic Wheat Engineered with CRISPR / Cas9." Plant Biotechnology Journal 16.4(2018):902-910.PMC, the contents of which are incorporated herein by reference.

[0269] Method for producing depitopied high molecular weight glutenin Disclosed herein is a method for producing a de-epitope-modified HMW glutenin, the method comprising: (a) culturing cells comprising an expression vector comprising a polynucleotide encoding any of the de-epitope-modified HMW glutenin modifying proteins disclosed herein, wherein the culturing is performed under conditions that allow expression of the de-epitope-modified HMW glutenin in the cells; and (b) expressing the de-epitope-modified HMW glutenin. Disclosed herein is a method for producing a de-epitope-modified HMW glutenin, the method comprising: (a) culturing cells comprising an expression vector comprising a polynucleotide encoding any of the de-epitope-modified HMW glutenin modifying proteins disclosed herein, wherein the culturing is performed under conditions that allow expression of the de-epitope-modified HMW glutenin in the cells; (b) expressing the de-epitope-modified HMW glutenin; and (c) recovering the expressed de-epitope-modified HMW glutenin. In some embodiments, the cells comprise plant cells. In some embodiments, the cells comprise wheat cells.

[0270] In some aspects, the method of producing depitope-depleted HMW glutenin produces depitope-depleted HMW glutenin that includes substitution mutations, or deletion mutations, or a combination thereof, in the repeating allergenic units of the HMW glutenin.

[0271] In some embodiments, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising a substitution mutation in a repeating antigenic unit of the de-epitope-modified HMW glutenin. In some embodiments, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising a deletion mutation in at least one repeating antigenic unit of the de-epitope-modified HMW glutenin.

[0272] In some aspects, the method of producing a de-epitope-modified HMW glutenin produces a de-epitope-modified HMW glutenin that includes substitution mutations in at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 repeating antigenic units of the de-epitope-modified HMW glutenin. In some aspects, the method of producing a de-epitope-modified HMW glutenin produces a de-epitope-modified HMW glutenin that includes deletion mutations of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 repeating antigenic units of the de-epitope-modified HMW glutenin.

[0273] In some embodiments, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising substitution mutations in at least 50%, 60%, 70%, 80%, 90% or all of the antigenic units of the de-epitope-modified HMW glutenin. In some embodiments, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising deletion mutations in at least 50%, 60%, 70%, 80%, 90% or all of the antigenic units of the de-epitope-modified HMW glutenin.

[0274] De-epitopeed HMW glutenin modified proteins are described in detail in the sections above. In some embodiments, the methods for producing de-epitopeed HMW glutenin produce any of the de-epitopeed HMW glutenin modified proteins disclosed herein.

[0275] In some embodiments, the method of producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising mutations at least at positions 1 and 9 of the repeating antigenic units of said HMW glutenin. In some embodiments, the method of producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising mutations at positions 1 and 9 of the repeating antigenic units of said HMW glutenin, and further comprising at least two additional mutations at any of positions 3, 4, or 7 of said repeating antigenic units. In some embodiments, the method of producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising mutations at positions 1 and 9 of the repeating antigenic units of said HMW glutenin, and further comprising at least two additional mutations at any of positions 2, 3, or 8 of said repeating antigenic units.

[0276] In some aspects, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising the amino acid sequence set forth in any of SEQ ID NOs: 38, 40-42, or 108-125. In some aspects, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising the amino acid sequence set forth in any of SEQ ID NOs: 109-112, 114-116, or 118-119. In some aspects, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising the amino acid sequence set forth in any of SEQ ID NOs: 126-142, 148-151, 155-168, or 170-172. In some embodiments, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising the amino acid sequence set forth in any one of SEQ ID NOs: 126-134, 137-138, 140-142, 148-151, and 155-166. In some embodiments, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising the amino acid sequence set forth in any one of SEQ ID NOs: 102, 103, 104, 105, 106, 107, 167, 168, 170, 171, or 172. In some embodiments, the method for producing de-epitope-modified HMW glutenin produces de-epitope-modified HMW glutenin comprising the amino acid sequence set forth in any one of SEQ ID NOs: 38, 40-42, 102-142, 148-151, or 155-172. In some aspects, the method for producing epitope-depleted HMW glutenin produces epitope-depleted HMW glutenin comprising an amino acid sequence set forth in any one of SEQ ID NOs: 102-107, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, 155-168, or 170-172.

[0277] To produce recombinant de-epitope HMW glutenin modified proteins, in some embodiments, production of the modified protein involves expression of a nucleotide construct containing a sequence engineered to enhance the stability, production, purification, or yield of the expressed protein. For example, expression of a fusion protein or cleavable fusion protein comprising the modified glutenin protein of some embodiments of the invention and a heterologous protein can be engineered. Such fusion proteins can be designed so that the fusion protein can be easily isolated by affinity chromatography, for example, by immobilization on a column specific for the heterologous protein. If a cleavage site is engineered between the modified glutenin protein and the heterologous protein, the modified glutenin protein can be released from the chromatography column by treatment with an appropriate enzyme or agent that destroys the cleavage site (see, e.g., Booth et al. (1988) Immunol. Lett. 19:65-70; and Gardella et al. (1990) J. Biol. Chem. 265:15854-15859).

[0278] The recombinant polypeptide is recovered after a suitable period of time during cultivation. The phrase "recovering the recombinant polypeptide" encompasses recovering the whole culture medium, e.g., the fermentation medium containing the modified HMW glutenin polypeptide. In some embodiments, recovery includes an additional step of separation or purification. In some embodiments, recovery does not include an additional step of separation or purification.

[0279] Notwithstanding the above, the modified HMW glutenin polypeptides of some embodiments disclosed herein can be purified using a variety of standard protein purification techniques, including, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse-phase chromatography, concanavalin A chromatography, chromatofocusing, and differential solubilization.

[0280] Methods for depitopylating HMW glutenin Disclosed herein in some aspects are methods for de-epitopling HMW glutenin, comprising mutating amino acid residues at positions 1 and 9 of at least one repeating antigenic unit of glutenin, wherein the unmutated repeating antigenic unit has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-33, 35, or 71-99, thereby producing a de-epitopled high molecular weight glutenin. In some aspects, the methods for de-epitopling HMW glutenin further comprise mutating at least two amino acids at positions 3, 4, or 7 of the repeating antigenic unit. In some aspects, the methods for de-epitopling HMW glutenin further comprise mutating at least two amino acids at positions 2, 3, and 8 of the repeating antigenic unit. In some aspects, the methods for de-epitopling HMW glutenin further comprise mutating at least two amino acids at positions 3, 5, and 8 of the repeating antigenic unit.

[0281] In some embodiments of the method for de-epitopizing HMW glutenin, the mutation comprises a substitution mutation. In some embodiments of the method for de-epitopizing HMW glutenin, the mutation comprises a deletion mutation in at least one antigenic unit. In some embodiments of the method for de-epitopizing HMW glutenin, the mutation comprises a deletion mutation in at least one antigenic unit.

[0282] In some aspects, the mutations to the repeating antigenic units do not disrupt the function of the HMW glutenin polypeptide (for example, but not limited to, do not disrupt the function of the modified HMW glutenin polypeptide compared to the function of the corresponding unmodified HMW glutenin polypeptide).

[0283] In some aspects, the mutations to the repeating antigenic units do not disrupt at least one of the following characteristics: (1) the ability of the HMW glutenin protein to strengthen dough; (2) the ability of the polypeptide to promote dough elasticity; (3) the ability of the polypeptide to promote dough rise; (4) the growth of a plant, such as, but not limited to, wheat, comprising the modified HMW glutenin (seed production, seed number, or seed size are not disrupted); (5) the native protein-protein interactions of the de-epitopeed HMW glutenin polypeptide (e.g., the modified HMW glutenin polypeptide retains the ability to form substantially the same protein-protein interactions as the corresponding unmutated polypeptide); (6) the three-dimensional structure of the HMW glutenin polypeptide (e.g., the modified de-epitopeed HMW glutenin polypeptide retains substantially the same three-dimensional structure as the corresponding unmodified HMW glutenin polypeptide); (7) the folding of the HMW glutenin polypeptide (e.g., the modified de-epitopeed HMW glutenin polypeptide retains substantially the same three-dimensional structure as the corresponding unmodified HMW glutenin polypeptide). (8) translation of the HMW glutenin polypeptide (e.g., the modified, depitope-modified HMW glutenin polypeptide is translated at the same timing, rate, level, etc. as the corresponding unmodified HMW glutenin polypeptide); (9) normal cellular localization of the HMW glutenin polypeptide (e.g., the modified, depitope-modified HMW glutenin polypeptide retains substantially the same cellular localization as the corresponding unmodified HMW glutenin polypeptide); (10) any post-translational modifications to the HMW glutenin polypeptide (e.g., the modified, depitope-modified HMW glutenin polypeptide retains substantially the same post-translational modification profile as the corresponding unmodified HMW glutenin polypeptide); and (11) allergenicity of the wheat HMW glutenin polypeptide (e.g., the modified, depitope-modified HMW glutenin retains substantially the same IgE antibody binding affinity as the corresponding unmodified HMW glutenin polypeptide).In some aspects, mutations to the repeating antigenic units destroy the allergenicity of the HMW glutenin polypeptide (e.g., the modified depitope-enhanced HMW glutenin has reduced IgE antibody binding affinity compared to the binding affinity of wheat extract).

[0284] In some aspects, mutations to the repeating antigenic units to de-epitope the HMW glutenin do not affect at least two, three, four, five, or more of the parameters set forth herein above, hi some aspects, mutations to the repeating antigenic units to de-epitope the HMW glutenin do not affect any of the parameters set forth herein above.

[0285] Methods for investigating the protein structure / folding / biochemical-biophysical properties of the de-epitope-modified glutenin disclosed herein include hydrodynamic studies (see, e.g., Field, JM, Tatham, AS & Shewry, PR 1987. Biochem. J. 247, 215-221; Castellia, F. et al., 2000. Thermochimica Acta 346, 153-160); NMR spectroscopy (see, e.g., Bekkers, AC et al. 1996, In Glutenin 96 - Proc. 6th Int. Wheat Glutenin Workshop, Sydney, September 1996, pp. 190-194; North Melbourne, Australia: Royal Australian Chemical Institute; Eliezer, D., Biophysical characterization of intrinsically disordered proteins. Curr Opin Struct Biol. 2009;19(1):23-30); circular dichroism measurements (see, e.g., Tatham, AS, Shewry, PR, 1985. J. Cereal Sci. 3, 104-113); heterologous expression analysis (see, e.g., Tatham, AS, Shewry, PR, 1985. J. Cereal Sci. 3, 104-113); static and dynamic light scattering measurements (see, e.g., Herrera, M.; Dodero, V. In Proceedings of the F. Bioact. Process. Qual. & Nutr., April 10-12, 2013; Sciforum Electronic Conferences Series; T.A. Egorov, FEBS Letters, Vol. 434, No. 1-2, 1998, pp. 215-217); small-angle X-ray scattering (see, e.g., Neil H. Thomson Biochimica et Biophysica Acta(BBA)-Protein Structure and Molecular Enzymology, Vol. 1430, No. 2, 1999, pp. 359-366; Eliezer, D., Curr Opin Struct Biol.2009;19(1):23-30); neutron very small angle scattering (see, e.g., Mohsen Daheshet et al., The Journal of Physical Chemistry B 2014 118(38), 11065-11076. DOI:10.1021 / jp5047134; Gibbs, BE & Showalter, SA 2015, Biochemistry 54, 1314-1326); fluorescence correlation spectroscopy (FCS) (see, e.g., Eliezer, D., Curr Opin Struct Biol. 2009;19(1):23-3); and single-molecule FRET (smFRET) (see, e.g., Gibbs, BE & Showalter, SA 2015, Biochemistry 54, 1314-1326). The entire contents of the above references are incorporated herein by reference.

[0286] In some aspects, the de-epitope HMW glutenin methods disclosed herein produce modified HMW glutenins that bind with lower affinity to celiac-associated MHC II proteins (e.g., HLA-DQ8; GenBank Accession Nos.: DQ8 alpha chain - MK501646.1 (SEQ ID NO: 34), beta chain - OU241996.1 (SEQ ID NO: 139)) or T cells from a celiac patient than the corresponding unmodified HMW glutenin binds to the MHC II protein or T cells from the same celiac patient. Furthermore, the de-epitope HMW glutenins may bind to DQ7.5 MHC II proteins with lower affinity than the corresponding unmodified HMW glutenins bind to DQ7.5 MHC II proteins.

[0287] In some embodiments, the de-epitope HMW glutenin method produces modified HMW glutenin that does not contain epitopes that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 30 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 30 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that contain 15-mer peptides that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 30 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that contain 14-mer peptides that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 30 μM. In some embodiments, the de-epitope-modified high molecular weight glutenin does not include an antigenic unit comprising a 13-, 12-, 11-, 10-, or 9-mer peptide that binds to MHC class DQ2 or DQ8 proteins with an IC50 of less than 30 μM. In some embodiments, peptides derived from the de-epitope-modified high molecular weight glutenin do not bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 30 μM. In some embodiments, the de-epitope-modified high molecular weight glutenin does not include an antigenic unit that binds to MHC class DQ2 or DQ8 proteins with an IC50 of less than 30 μM.

[0288] In some embodiments, the de-epitope HMW glutenin method produces modified HMW glutenin that does not contain epitopes that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 25 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 25 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that contain 15-mer peptides that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 25 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that contain 14-mer peptides that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 25 μM. In some embodiments, the de-epitope-modified high molecular weight glutenin does not comprise an antigenic unit comprising a 13-, 12-, 11-, 10-, or 9-mer peptide that binds to MHC class DQ2 or DQ8 proteins with an IC50 of less than 25 μM. In some embodiments, peptides derived from the de-epitope-modified high molecular weight glutenin do not bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 25 μM. In some embodiments, the de-epitope-modified high molecular weight glutenin does not comprise an antigenic unit that binds to MHC class DQ2 or DQ8 proteins with an IC50 of less than 25 μM.

[0289] In some embodiments, the de-epitope HMW glutenin method produces modified HMW glutenin that does not contain epitopes that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 20 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 20 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that contain 15-mer peptides that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 20 μM. In some embodiments, the de-epitope HMW glutenin does not contain antigenic units that contain 14-mer peptides that bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 20 μM. In some embodiments, the de-epitope-modified high molecular weight glutenin does not include an antigenic unit comprising a 13-, 12-, 11-, 10-, or 9-mer peptide that binds to MHC class DQ2 or DQ8 proteins with an IC50 of less than 20 μM. In some embodiments, peptides derived from the de-epitope-modified high molecular weight glutenin do not bind to MHC class DQ2 or DQ8 proteins with an IC50 of less than 20 μM. In some embodiments, the de-epitope-modified high molecular weight glutenin does not include an antigenic unit that binds to MHC class DQ2 or DQ8 proteins with an IC50 of less than 20 μM.

[0290] Thus, the affinity value, measured in units of concentration, is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% higher for the de-epitope-modified HMW glutenin protein binding to a celiac-associated MHCII protein (e.g., HLA-DQ2 or HLA-DQ8) or T cells from a celiac patient than the corresponding unmodified HMW glutenin binding to T cells from the same celiac patient.

[0291] Those skilled in the art will understand that higher affinity values ​​indicate weaker binding, in that a higher concentration is required to reach the same number of binding receptors, or in the case of IC50, to reduce the level of bound control peptide by half. In some aspects, the de-epitope-modified HMW glutenins disclosed herein have reduced binding affinity for celiac-associated MHC II proteins or T cells from celiac patients compared to non-de-epitope-modified HMW glutenins. In some aspects, peptides derived from the de-epitope-modified HMW glutenins disclosed herein have reduced binding affinity for T cells from celiac patients compared to non-de-epitope-modified HMW glutenins. In some aspects, the repeating antigenic units derived from the de-epitope-modified HMW glutenins disclosed herein have reduced binding affinity for celiac-associated MHC II proteins or T cells from celiac patients compared to non-de-epitope-modified HMW glutenins.

[0292] In some embodiments, when HMW proteins are digested and then tested for binding to HLA-DQ2.5 / 8, there are peptides that bind to these MHC II proteins but do not activate T cells because they do not bind to T cells with the required affinity. In some embodiments, an antigenic unit or de-epitopeed HMW glutenin that shows binding to HLA-DQ2.5 / 8 of greater than 30 uM indicates that the antigenic unit or de-epitopeed HMW glutenin has low loading capacity for MHC II and, as a result, cannot be effectively recognized by T cells, thereby resulting in T cell deactivation.

[0293] In one aspect, binding of the modified depitope-enhanced HMW glutenin to celiac-associated MHC II proteins (e.g., HLA-DQ2 or HLA-DQ8) or T cells is abrogated. Methods for measuring binding of HMW glutenin antigenic unit peptides / HMW glutenin polypeptides to celiac-associated MHC II proteins (e.g., HLA-DQ2 or HLA-DQ8) or T cells are known in the art, and include, for example, 1) detection of peptide / MHC II complexes using a combination of gel filtration and competitive binding to well-defined radiolabeled reference peptides (Sidney, John et al., "Measurement of MHC / peptide interactions by gel filtration or monoclonal antibody capture." Current protocols in immunology 100.1 (2013):18-3); 2) use of MHC II tetramers with gluten peptide fusions to detect and quantify binding to gluten-specific CD4+ T cells by flow cytometry (Raki, Melinda et al., "Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of celiac disease patients." Proceedings of the National Academy of Sciences 104.8(2007):2831-2836.); 3) ELISpot or ELISA assay to measure activation of gluten-specific CD4+ T cells by probing IFN-γ secretion (Anderson, RP et al., "T cells in peripheral blood after gluten challenge in coeliac disease." Gut 54.9(2005):1217-1223.); 4) related APCs (e.g., HLA DQ8 or HLA DQ2).These include gluten-specific T cell proliferation assays in the presence of gluten peptides (Kooy-Winkelaar, Yvonne et al., "Gluten-specific T cell cross-react between HLA-DQ8 and the HLA-DQ2α / DQ8β transdimer." The Journal of Immunology 187.10(2011):5123-5129).

[0294] According to some embodiments, the de-epitope HMW glutenin methods disclosed herein produce modified HMW glutenins that do not contain 15-mer peptides present in the repeating antigenic units that bind to MHC class DQ2 or DQ8 with an IC50 of less than 20 μM, less than 30 μM, or even less than 40 μM - see Example 1 herein. According to some embodiments, the de-epitope HMW glutenin methods disclosed herein produce modified HMW glutenins that do not contain repeating motifs present in the repeating antigenic units that bind to MHC class DQ2 or DQ8 with an IC50 of less than 20 μM, less than 30 μM, or even less than 40 μM. In some embodiments, the de-epitope HMW glutenin methods disclosed herein produce modified HMW glutenins that do not contain 9-15-mer peptides present in the repeating antigenic units that bind to MHC class DQ2 or DQ8 with an IC50 of less than 20 μM, less than 30 μM, or even less than 40 μM. In some aspects, the de-epitope HMW glutenin methods disclosed herein produce modified HMW glutenins that do not contain repeating antigenic units that bind to MHC class DQ2 or DQ8 with an IC50 of less than 20 μM, less than 30 μM, or even less than 40 μM.

[0295] In some embodiments of the depitope HMW glutenin method, the method produces a modified HMW glutenin that activates T cells from a celiac patient to a lesser extent (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%) than a corresponding unmutated polypeptide activates T cells from the same celiac patient. Exemplary T cell activation assays include measuring IFN-γ using an ELISA.

[0296] As described throughout, de-epitopation of HMW glutenin is achieved in some embodiments by substituting the first amino acid (i.e., position 1) and the ninth amino acid (i.e., position 9) of at least one repeating antigenic unit of the HMW glutenin. In certain embodiments, de-epitopation of HMW glutenin is achieved by substituting the first amino acid (i.e., position 1) and the ninth amino acid (i.e., position 9), as well as substituting at least two additional amino acids within at least one repeating antigenic unit of the HMW glutenin.

[0297] Substitutions may be conservative or non-conservative.

[0298] The phrase "non-conservative substitution" can encompass the replacement of an amino acid present in the parent (WT) HMW glutenin sequence with another naturally occurring or non-naturally occurring amino acid that has different electrochemical and / or steric properties. Thus, the side chain of the substituted amino acid can be significantly larger (or smaller) than the side chain of the naturally occurring amino acid being substituted and / or can have a functional group with significantly different electronic properties than the amino acid being substituted. Examples of this type of non-conservative substitution include the substitution of phenylalanine or cyclohexylmethylglycine for alanine, isoleucine for glycine, or NH CH[(CH)COOH]CO for aspartic acid.

[0299] It will be understood that conservative substitutions may also be contemplated herein. Conservative substitution tables providing functionally similar amino acids are well known in the art. Guidance on which amino acid changes are likely to be phenotypically silent can also be found in Bowie et al., 1990, Science 247:1306-1310. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles. Exemplary conservative substitutions include, but are not limited to, 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine ​​(C), methionine (M) (see, e.g., Creighton, Thomas E. Proteins: structures and molecular properties. Macmillan, 1993). Amino acids can be substituted based on properties associated with their side chains, for example, amino acids with polar side chains, such as serine (S), threonine (T), tyrosine (Y), aspartic acid (D), and glutamic acid (E); amino acids based on the charge of their side chains, for example, the positively or negatively charged amino acids arginine (R), histidine (H), lysine (K), aspartic acid (D), and glutamic acid (E); small amino acids serine (S), threonine (T), alanine (A), glycine (G), and valine (V); aliphatic amino acids methionine (M), valine (V), leucine (L), isoleucine (I), and alanine (A); aromatic amino acids phenylalanine (F), tryptophan (W), and tyrosine (Y); and amino acids with hydrophobic side chains, such as valine (V), leucine (L), methionine (M), and isoleucine (I). As indicated, the changes are typically minor in nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein.

[0300] In some embodiments of the method for de-epitopling HMW glutenin, the mutation comprises a substitution of the amino acid residue at position 9 of the antigenic unit, wherein the substitution comprises a replacement with a positively charged amino acid, a small amino acid, or glutamic acid. In some embodiments of the method for de-epitopling HMW glutenin, the positively charged amino acid comprises arginine, histidine, or lysine; or the small amino acid comprises serine or threonine; or the substitution is a combination of two or more antigenic units being mutated. In other embodiments of the method for de-epitopling HMW glutenin, the mutation comprises a substitution at position 9 of the antigenic unit, wherein the substitution comprises a replacement with arginine, histidine, serine, threonine, or glutamic acid.

[0301] In some embodiments of the method for de-epitopizing HMW glutenin, the mutation comprises a substitution at position 1 of the antigenic unit, the substitution comprising a replacement with histidine, proline, serine, alanine, lysine, or glutamic acid. In some embodiments of the method for de-epitopizing HMW glutenin, (a) the substitution at position 1 of the antigenic unit is a replacement with histidine and the substitution at position 9 of the antigenic unit is a replacement with histidine; (b) the substitution at position 1 of the antigenic unit is a replacement with proline and the substitution at position 9 of the antigenic unit is a replacement with arginine; (c) the substitution at position 1 of the antigenic unit is a replacement with alanine and the substitution at position 9 of the antigenic unit is a replacement with arginine; (d) the substitution at position 1 of the antigenic unit is a replacement with serine and the substitution at position 9 of the antigenic unit is a replacement with threonine; (e) the substitution at position 1 of the antigenic unit is a replacement with glutamic acid. or (f) the substitution at position 1 of the antigenic unit is a replacement with proline and the substitution at position 9 of the antigenic unit is a replacement with threonine; (g) the substitution at position 1 of the antigenic unit is a replacement with glutamic acid and the substitution at position 9 of the antigenic unit is a replacement with lysine or arginine; (h) the substitution at position 1 of the antigenic unit is a replacement with glutamic acid or lysine and the substitution at position 9 of the antigenic unit is a replacement with histidine; or (i) if two or more repeating antigenic units are mutated, any combination of (a) to (h).

[0302] In some embodiments of the method for depitopizing HMW glutenin, the method further comprises mutating at least two amino acids at positions 3, 4, or 7 of the repeating antigenic unit. In some embodiments of the method, the mutation comprises substituting the amino acid residues at these positions. In some embodiments of the method, (a) the substitution at position 3 is a replacement of the amino acid with a polar amino acid or a positive amino acid; or (b) the substitution at position 4 is a replacement of the amino acid with a negatively charged amino acid or glycine; or (c) the substitution at position 7 is a replacement of the amino acid with glycine; or if two or more repeating antigenic units are mutated, the substitution is any combination of (a)-(c).

[0303] In some embodiments of the method for de-epitope HMW glutenin, the method further comprises mutating at least two amino acids at positions 2, 3, or 8 of the repeating antigenic unit. In some embodiments of the method, the mutation is a substitution, and (a) the substitution at position 2 is replacing the amino acid with an aromatic amino acid or a positively charged amino acid; or (b) the substitution at position 3 is replacing the amino acid with a polar amino acid or a positively charged amino acid; or (c) the substitution at position 8 is replacing the amino acid with a small amino acid or an aliphatic amino acid; or if two or more repeating antigenic units are mutated, the substitution comprises any combination of (a)-(c). In some embodiments of the method for de-epitope HMW glutenin, the substitution at position 2 is replacing the amino acid with tryptophan and the substitution at position 3 is replacing the amino acid with histidine.

[0304] In some embodiments of the method for de-epitope HMW glutenin, the method further comprises mutating at least two amino acids at positions 3, 5, or 8 of the repeating antigenic unit. In some embodiments of the method, the mutation is a substitution, and (a) the substitution at position 3 is a replacement of the amino acid with a polar amino acid or a positively charged amino acid; or (b) the substitution at position 5 is a replacement of the amino acid with a hydrophobic amino acid; or (c) the substitution at position 8 is a replacement of the amino acid with a small amino acid or an aliphatic amino acid; or if two or more repeating antigenic units are mutated, the substitution comprises any combination of (a)-(c). In some embodiments of the method for de-epitope HMW glutenin, the substitution at position 3 is a replacement of the amino acid with arginine and the substitution at position 5 is a replacement of the amino acid with leucine.

[0305] In some embodiments of the method for epitope-depleting HMW glutenin, the epitope-depleted HMW glutenin comprises any of the amino acid sequences set forth in SEQ ID NOs: 38, 40 to 42, 52, 102 to 107, 108 to 125, 126 to 142, 148 to 151, and 155 to 172. In some embodiments of the method for epitope-depleting HMW glutenin, the epitope-depleted HMW glutenin comprises any of the amino acid sequences set forth in SEQ ID NOs: 52, 102 to 107, 109 to 112, 114 to 116, 118 to 119, 126 to 134, 137 to 138, 140 to 142, 148 to 151, 155 to 168, and 170 to 172. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 38, 40-42. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 52. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 102-107. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 109-112. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 114-116. In some embodiments of the method for de-epitopising HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 118-119. In some embodiments of the method for de-epitopising HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 108-125. In some embodiments of the method for de-epitopising HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 126-142. In some embodiments of the method for de-epitopising HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 126-134.In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 137-138. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 140-142. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 148-151. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 155-172. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 155-168. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 170 to 172. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 126 to 134, 137, 138, 148, and 155 to 162. In some embodiments of the method for de-epitopling HMW glutenin, the de-epitopled HMW glutenin comprises the amino acid sequence set forth in any of SEQ ID NOs: 109, 111, 115, 116, 118, and 119.

[0306] In some embodiments of the method for epitope-depleting HMW glutenin, the epitope-depleted HMW glutenin comprises an amino acid sequence set forth in any one of SEQ ID NOs: 102 to 107, 167 to 168, and 170 to 172, and the repeat antigenic units are deleted. In some embodiments of the method for epitope-depleting HMW glutenin, the epitope-depleted HMW glutenin comprises an amino acid sequence set forth in any one of SEQ ID NOs: 109 to 112, 114 to 116, 118 to 119, 126 to 134, 137 to 138, 140 to 142, 148 to 151, and 155 to 166, and the repeat antigenic units comprise substitution mutations.

[0307] In some embodiments of the method of de-epitopizing HMW glutenin, the method further includes analyzing the binding of the de-epitopized high molecular weight glutenin to T cells from a celiac patient; and identifying the de-epitopized high molecular weight glutenin as having reduced immunogenicity if the de-epitopized high molecular weight glutenin activates T cells from a celiac patient to a lesser extent than a corresponding unmutated high molecular weight glutenin activates T cells from a celiac patient, as measured using an HLA-DQ-peptide tetramer-based assay, or by an interferon-γ ELISA assay, or any combination thereof.

[0308] In some embodiments of the method of de-epitope HMW glutenin, the mutations are made in at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 repeating antigenic units. In some embodiments of the method of de-epitope HMW glutenin, the mutations are made in more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 repeating antigenic units. In some embodiments of the method for depitopizing HMW glutenin, mutations are made in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more than 30 repeating antigenic units.

[0309] In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are made at 1 to 30 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are made at 1 to 20 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are made at 1 to 5 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are made at 1 to 10 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are made at 1 to 15 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are made at 1 to 20 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are made at 5 to 20 antigenic units. In some embodiments of the method for de-epitope of HMW glutenin, the mutations are made at 5 to 10 antigenic units. In some embodiments of the method for de-epitope of HMW glutenin, the mutations are made at 5 to 15 antigenic units. In some embodiments of the method for de-epitope of HMW glutenin, the mutations are made at 10 to 20 antigenic units. In some embodiments of the method for de-epitope of HMW glutenin, the mutations are made at 15 to 20 antigenic units. In some embodiments of the method for de-epitope of HMW glutenin, the mutations are made at more than 20 antigenic units. In some embodiments of the method for de-epitope of HMW glutenin, the mutations are made at 5 to 30 antigenic units. In some embodiments of the method for de-epitope of HMW glutenin, the mutations are made at 10 to 30 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are performed at 15 to 30 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are performed at 20 to 30 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are performed at 25 to 30 antigenic units. In some embodiments of the method for de-epitopizing HMW glutenin, the mutations are performed at 10 to 25 antigenic units.

[0310] In some embodiments of the method for de-epitopizing HMW glutenin, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or all of the antigenic units present in the HMW glutenin protein are mutated (i.e., de-epitopized).

[0311] In some embodiments of the method for depitopizing HMW glutenin, mutations are performed on at least 5-10 repeating antigenic units.

[0312] food Disclosed herein is the use of modified, de-epitope HMW glutenin to produce foods that are particularly beneficial for subjects suffering from gluten intolerance, including gluten intolerance, such as those suffering from CD or related irritation of either the intestine or bowel. These foods may also benefit subjects suffering from wheat allergy, such as, but not limited to, wheat-dependent exercise-induced anaphylaxis (WDEIA), or subjects suffering from non-celiac gluten intolerance. In some aspects, the de-epitope HMW glutenin polypeptides described herein are intended for use in preparing foods suitable for consumption by subjects with celiac disease. Thus, the de-epitope HMW glutenin may be used in preparing meat products, cheeses, and vegetarian substitutes for meat products.

[0313] In certain aspects, the depitopled gluten polypeptides can be used to prepare food flour. In some aspects, flours comprising any of the depitopled HMW glutenins disclosed herein are disclosed herein. In some aspects, flours comprising any of the depitopled HMW glutenins disclosed herein are derived from plants lacking wild-type HMW glutenins. In some aspects, flours comprising any of the depitopled HMW glutenins disclosed herein are derived from plants lacking other gluten protein components. In some aspects, flours comprising any of the depitopled HMW glutenins disclosed herein are derived from plants lacking a reduced percentage of gluten protein. Non-limiting examples of plants (e.g., grains) from which flours comprising depitopled HMW glutenins can be derived include, but are not limited to, amaranth, wheat, buckwheat, rice (brown rice, white rice, wild rice), corn, millet, quinoa, sorghum, and teff. In some embodiments, the plants from which the flour comprising the depitopled HMW glutenin can be derived contain reduced amounts of gluten protein, ie, about a 75% reduction in gluten protein.

[0314] In some aspects, disclosed herein is a modified wheat expressing a modified depitope-treated HMW glutenin disclosed herein, wherein at least one antigenic unit is mutated. In some aspects, disclosed herein is a modified wheat expressing a modified depitope-treated HMW glutenin disclosed herein, wherein multiple antigenic units are mutated. In some aspects, disclosed herein is a modified wheat expressing a modified depitope-treated HMW glutenin disclosed herein, wherein the modified HMW glutenin comprises antigenic unit mutations comprising substitution mutations or deletion mutations, or a combination thereof, as described throughout the specification for the depitope-treated HMW glutenin disclosed herein. In some aspects, disclosed herein is a modified wheat grass expressing a modified depitope-treated HMW glutenin disclosed herein.

[0315] In some aspects, disclosed herein is a flour comprising any of the depitopied HMW glutenins disclosed herein, wherein the flour is derived from a modified wheat grass.

[0316] In some aspects, disclosed herein is an engineered corn plant that expresses an engineered depitope-modified HMW glutenin disclosed herein, wherein at least one antigenic unit is mutated. In some aspects, disclosed herein is an engineered corn plant that expresses an engineered depitope-modified HMW glutenin disclosed herein, wherein multiple antigenic units are mutated. In some aspects, disclosed herein is an engineered corn plant that expresses an engineered depitope-modified HMW glutenin disclosed herein, wherein the engineered HMW glutenin comprises antigenic unit mutations comprising substitution mutations, deletion mutations, or combinations thereof, as described throughout the specification for the depitope-modified HMW glutenins disclosed herein. In some aspects, disclosed herein is an engineered corn plant that expresses an engineered depitope-modified HMW glutenin disclosed herein.

[0317] In some aspects, disclosed herein is a flour comprising any of the depitopied HMW glutenins disclosed herein, wherein the flour is derived from a modified corn plant.

[0318] Those skilled in the art will appreciate that the term "flour" can encompass foodstuffs that are free-flowing powders, typically obtained by milling. Flour is most often used in bakery foods such as bread, cakes, and pastries, but is also used in other foods such as pasta, noodles, and breakfast cereals.

[0319] Examples of flour include hard flour, all-purpose flour, unbleached flour, self-rising flour, refined flour, whole wheat flour, and semolina. In some embodiments, flour derived from a non-gluten plant is provided, comprising at least one depitopled HMW glutenin polypeptide.

[0320] In some aspects, a non-gluten plant is transformed with a polynucleotide encoding a depitopied HMW glutenin polypeptide disclosed herein and flour is produced therefrom (e.g., by grinding, mincing, milling, etc.).

[0321] In some aspects, flour is produced from a non-gluten plant (e.g., by grinding, mincing, milling, etc.) and at least one modified, depitope-modified HMW glutenin polypeptide disclosed herein is added.

[0322] Those skilled in the art will appreciate that non-gluten plants contain reduced amounts of gluten protein. In some embodiments, non-gluten plants contain no gluten protein (levels are undetectable). In some embodiments, non-gluten plants contain 75% to 100% reduction in gluten protein. In some embodiments, non-gluten plants contain 75% reduction in gluten protein. In some embodiments, non-gluten plants contain 75%, 80%, 85%, 90%, 95%, or 99% reduction in gluten protein. In some embodiments, non-gluten plants contain at least 75% reduction in gluten protein. In some embodiments, non-gluten plants contain at least 75%, 80%, 85%, 90%, 95%, or 99% reduction in gluten protein. In some embodiments, non-gluten plants contain more than 75% reduction in gluten protein. In some aspects, the non-gluten plant comprises a 75%, 80%, 85%, 90%, 95%, or greater than 99% reduction in gluten protein.

[0323] In some embodiments, wheat is genetically modified to express any of the de-epitope HMW glutenins disclosed herein.In some embodiments, in the wheat that is genetically modified to express de-epitope HMW glutenins, the expression of corresponding non-mutated HMW glutenin polypeptide is down-regulated compared with wild-type wheat.In certain embodiments, genetically modified wheat comprises an RNA silencing agent for non-mutated polypeptide.In some embodiments, genetically modified wheat is genetically modified by DNA editing agent.

[0324] In some embodiments, corn plants are genetically modified to express any of the epitope-reduced HMW glutenins disclosed herein.In some embodiments, in the corn plants that are genetically modified to express epitope-reduced HMW glutenins, the expression of corresponding non-mutated HMW glutenin polypeptides is down-regulated compared with wild-type corn plants.In certain embodiments, the genetically modified corn plants comprise an RNA silencing agent for non-mutated polypeptides.In some embodiments, the genetically modified corn plants are genetically modified by DNA editing agents.

[0325] In some aspects, flour produced from wheat genetically modified to express de-epitope HMW glutenin is disclosed herein. In some aspects, flour produced from wheat genetically modified to express at least one de-epitope HMW glutenin is disclosed herein. In some aspects, flour produced from wheat genetically modified to express multiple de-epitope HMW glutenin polypeptides is disclosed herein.

[0326] In some embodiments, disclosed herein is a dough produced from wheat comprising a de-epitope-modified HMW glutenin. In some embodiments, disclosed herein is a dough produced from wheat comprising at least one de-epitope-modified HMW glutenin. In some embodiments, disclosed herein is a dough produced from wheat comprising a plurality of de-epitope-modified HMW glutenin polypeptides.

[0327] In certain aspects, disclosed herein is a dough comprising flour comprising depitopled HMW glutenin. In certain aspects, disclosed herein is a dough comprising flour comprising depitopled HMW glutenin and no WT HMW glutenin polypeptides.

[0328] The amount and type of de-epitope-modified HMW glutenin polypeptide can be adjusted to alter the quality of the flour or dough produced therefrom. Thus, in some aspects, the use of any of the de-epitope-modified HMW glutenin polypeptides disclosed herein, or a combination thereof, improves dough compared to dough without the addition of the de-epitope-modified HMW glutenin polypeptide. Those skilled in the art will understand that improving dough includes producing dough with properties (e.g., strength, elasticity) similar to dough made from wheat flour compared to the behavior of dough made from non-wheat flour (e.g., almond flour, teff flour).

[0329] According to yet another aspect, flour is produced from wheat that has been genetically modified to express at least one depitopled HMW glutenin polypeptide disclosed herein. In some aspects, the genetically modified wheat has been further engineered to downregulate or eliminate expression of wild-type HMW glutenin polypeptides (as described herein). In some aspects, the wheat can be used to produce other edible products, such as beer.

[0330] In certain aspects, the dough is made from any of the flours described herein.

[0331] Thus, in some embodiments, the dough strengthening ability is not reduced by more than 50%, 60%, 70%, 80% compared to the wild-type polypeptide. Bread produced from flour containing the modified polypeptide is typically at least 50% more resilient than bread produced from flour lacking the HMW glutenin.

[0332] Those skilled in the art will understand that the term "dough" encompasses its commonly used meaning, i.e., a composition that contains, as a minimum of essential ingredients, flour and a liquid source, such as at least water, which is used for kneading and shaping. Dough is characterized by its malleability.

[0333] Those skilled in the art will understand that the term "malleable" in reference to dough can encompass the ability of the dough to undergo adaptive changes without necessarily breaking easily, and thus the pliability, elasticity and / or flexibility of the dough, which allows the dough to be subjected to any one of the following processing steps: stretching, shaping, stretching, sheeting, morphing, fitting, kneading, molding, modeling, etc. Shaping of the dough can be by any tool having a predetermined shape, or by rolling pin or by hand.

[0334] The dough of some embodiments may include additional ingredients such as salt, vegetable starch, flavorings, vegetables or vegetable parts, oil, vitamins, and olives.

[0335] The dough may further comprise a leavening agent, examples of which include draft beer, buttermilk, ginger beer, kefir, sourdough starter, yeast, whey protein concentrate, yogurt, biological leavening agents, chemical leavening agents, baking soda, baking powder, baker's ammonia, potassium bicarbonate, and any combination thereof.

[0336] In some embodiments, the dough is combined with at least one additional food ingredient, including a flavoring, a vegetable, a vegetable part, a mix of vegetables, a mix of vegetable parts, an oil, a vegetable starch, a vitamin, or an olive.

[0337] Processed products produced from dough containing the depitopized glutenin described herein include, but are not limited to, bread, pizza bread crust, pasta, tortillas, panini bread, pretzels, pie, and sandwich bread products.

[0338] In some embodiments for processed dough products prepared by processing dough comprising depitopized HMW glutenin, the processing step includes combining the dough with food ingredients, leaving, kneading, extruding, molding, forming, cooking, simmering, boiling, broiling, baking, frying, and any combination thereof.

[0339] In some embodiments for processed dough products prepared by processing dough containing depitopened HMW glutenin, the processing is in forms including bread, pizza bread crust, pasta, tortilla, panini bread, pretzels, pie, and sandwich bread products.

[0340] In some aspects, disclosed herein are methods of producing flour, the methods comprising processing wheat comprising depitopized HMW glutenin as described herein, thereby producing flour. In some aspects, the processing comprises grinding or milling.

[0341] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" can include a plurality of compounds, including mixtures thereof.

[0342] Throughout this application, various embodiments of de-epitope-modified HMW glutenin, methods for producing the same, and methods for de-epitope-modifying HMW glutenin are presented in a range format, e.g., by the number of mutated antigenic units or the number of mutated amino acids within an antigenic unit. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to specifically disclose all possible subranges as well as individual numbers within that range. For example, the description of a range such as 1 to 6 should be considered to specifically disclose subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numbers within that range, e.g., 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0343] Whenever a numerical range is indicated herein, this is intended to include any recited number (fractional or integer) within the indicated range. The phrases "ranging between" a first indicated number and a second indicated number and "ranging to" a first indicated number "from" a second indicated number are used interchangeably herein and are intended to include the first indicated number and the second indicated number and all fractional and integer numbers therebetween.

[0344] In some embodiments, the term "about" refers to a deviation of between 0.0001 and 5% from the indicated number or range of numbers. In some embodiments, the term "about" refers to a deviation of between 1 and 10% from the indicated number or range of numbers. In some embodiments, the term "about" refers to a deviation of up to 25% from the indicated number or range of numbers.

[0345] example Reference is now made to the following examples, which together with the above description illustrate, in a non-limiting manner, some embodiments of depitopised high molecular weight (HMW) glutenin peptides.

[0346] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological, and recombinant DNA techniques. Such techniques are fully explained in the literature. See, e.g., "Molecular Cloning: A Laboratory Manual," Sambrook et al. (1989); "Current Protocols in Molecular Biology," Vols. I-III, edited by Ausubel, R.M. (1994); Ausubel et al., "Current Protocols in Molecular Biology," John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning," John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA," Scientific American Books, New York; Birren et al. (eds.), "Genome Analysis: A Laboratory Manual Series," Vols. 1-4, Cold Spring Harbor Laboratory. Press, New York (1998); the methodologies set forth in U.S. Patent Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook," Vols. I-III, edited by Cellis, JE (1994); "Culture of Animal Cells - A Manual of Basic Technique," Freshney, Wiley-Liss, NY (1994), 3rd ed.; "Current Protocols in Immunology," Vols. I-III, Coligan JE(1994); Stites et al. (eds.), Basic and Clinical Immunology (8th ed.), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds.), Selected Methods in Cellular Immunology, W.H. Freeman and Co., New York (1980); available immunoassays are widely described in the patent and scientific literature, e.g., U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,2 Nos. 62; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; "Oligonucleotide "Nucleic Acid Synthesis" edited by Gait, MJ (1984); "Nucleic Acid Hybridization" edited by Hames, BD and Higgins SJ (1985); "Transcription and Translation" edited by Hames, BD and Higgins SJ (1984); "Animal Cell Culture" edited by Freshney, RI (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A Practical Guide to Molecular Cloning" Perbal, B.See, for example, (1984) and "Methods in Enzymology," Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications," Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual," CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All information contained therein is incorporated herein by reference.

[0347] Example 1 Materials and Methods Computational design of peptides for reduced HLA-DQ8 binding

[0348] Close and more distantly related sequence homologs of the high molecular weight glutenin subunit (uniprot accessions X12929, SEQ ID NO: 48 and X12928, SEQ ID NO: 47) were identified by searches performed at the protein level using either BLAST searches (Altschul, Stephen F. et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs." Nucleic Acids Research 25.17 (1997): 3389-3402) or HHblits, which uses an iterative sequence search based on hidden Markov models (HMMs) (Remmert, Michael et al., "HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment." Nature Methods 9.2 (2012): 173-175).-10 Sequences with an expected value exceeding 0.05 were discarded. Next, sequences were aligned using Clustal Omega (Sievers, Fabian et al., "Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega." Molecular Systems Biology 7.1 (2011):539), followed by identifying and extracting all sequence segments aligned to the epitope of interest. Design of peptides predicted to bind to HLA-DQ8 with reduced affinity was performed by in silico structural modeling and energy calculations via the Maestro graphical interface to the Schrodinger software suite (Schrodinger, LLC, "The Maestro suite of programs: A powerful, all-purpose molecular modeling environment." New York: Schrodinger LLC (2005)). The solved crystal structure of HLA-DQ8 bound to the alpha gliadin epitope HLA-DQ8-glia-α1 (PDB accession 4z7v) was used as the starting structure. The structure of the deamidated epitope DQ8-glut-H1 (GQEGYYPTSPEQS; SEQ ID NO: 50) was modeled using the "Mutate Residues" module with simple side-chain mutations of the alpha-gliadin peptide structure. Structural refinement was performed on the starting structure using the Protein Preparation Wizard. Next, the Residue Scanning tool was used to perform Monte Carlo sampling in the peptide sequence search, combining conservative mutations and calculating the predicted change in binding energy, ΔΔG, upon mutation. Candidate peptide sequences were selected for experimental validation based on the predicted change in binding energy (an increase of at least 10 relative energy units was required), followed by manual inspection of the generated interaction model.

[0349] Due to the nature of the assay, 15-mer peptides were determined to be optimal for affinity (IC50 binding) assays. Peptides were synthesized as 2 mg-scale purified material with free acid C-termini (A&A labs, USA). Those skilled in the art will understand that the 15-mers used contained shorter, de-epitopeed high molecular weight glutenin peptide sequences (mutated repeating antigenic units) as described throughout. For example, Table 2 provides a list of 15-mers and the shorter mutated repeating antigenic units present therein.

[0350] [Table 2]

[0351] Measurement of major histocompatibility complex (MHC) / peptide interactions:

[0352] In vitro testing of the designed modified gluten peptides was performed using a major histocompatibility complex (MHC II) binding assay (Sidney, John et al., "Measurement of MHC / peptide interactions by gel filtration or monoclonal antibody capture." Current protocols in immunology 100.1 (2013): 18-3).

[0353] Briefly, competition assays using different concentrations of wild-type (WT) and modified glutenin peptides were performed by diluting the peptides in NP40 buffer and incubating them with purified MHC II and radiolabeled known MHC-binding peptides (peptide probes) for 2–4 days. MHC II molecules were purified by affinity chromatography, and the peptides were radiolabeled using the chloramine T method. After the incubation period, bound and unbound radiolabeled species were separated, and their relative amounts were determined either by size-exclusion gel filtration chromatography or monoclonal antibody capture of MHC. The percent bound radioactivity was then determined. For each modified peptide, IC50 values ​​for the WT and modified peptides were calculated. Known glutenin peptide epitopes (SEQ ID NOs: 49 and 50, known in the art) were analyzed for MHC binding as a positive control, in both deamidated (SEQ ID NO: 50 deamidated native peptide) or non-deamidated (SEQ ID NO: 49) form. An IC value greater than 4-5 times greater than the native peptide (SEQ ID NO: 49) indicates that binding of the engineered peptide sequence is impaired with respect to binding of the native glutenin peptide. Non-binding was defined as an IC of ≥ 30,000 nM.

[0354] result Table 3 shows the IC50 measured for several peptide variants predicted to have impaired binding to MHC II. Values ​​greater than the deaminated peptide (SEQ ID NO: 50) indicate that binding of the engineered peptide chain is impaired relative to binding of the peptide derived from native glutenin. For each peptide, the number of alterations relative to the WT native peptide (SEQ ID NO: 49) is listed.

[0355] [Table 3]

[0356] These results demonstrate that introducing three or more mutations into an antigenic epitope reduces binding affinity to MHC II to levels where binding is undetectable (see, e.g., results for SEQ ID NOs: 52, 54, 55, and 56). Variants P1c and P1e exhibit significantly reduced binding affinity to MHC II, to a level similar to that of the non-deamidated peptide, to a level that can still activate T cells, but to a lesser extent than the deamidated peptide. Variant P1h exhibits HLA-DQ2.2 binding affinity at a level similar to that of the deamidated peptide.

[0357] Table 4 shows the IC50s measured for additional variants predicted to have impaired binding to MHCII. As shown in Table 2, IC50 values ​​4-5 times greater than the deaminated peptide indicate that binding of the engineered peptide chain is impaired relative to binding of the peptide derived from native glutenin. The underlined amino acids represent residues that are altered (substituted) compared to the native peptide shown in SEQ ID NO:49.

[0358] [Table 4]

[0359] Example 2 Exemplary High Molecular Weight Glutenin Peptides and Polypeptides That Demonstrate Abrogation of T Cell Activation Fractionation of gluten proteins from wheat flour

[0360] High molecular weight glutenin was prepared from wheat flour as described in (Schalk, Kathrin et al., "Isolation and characterization of gluten protein types from wheat, rye, barley, and oats for use as reference materials." PloS one 12.2 (2017): e0172819). Briefly, flour was defatted using an n-pentane / ethanol solution. The defatted flour was extracted with a salt solution. The precipitate was extracted with ethanol / water, and the resulting supernatant was concentrated, dialyzed against 0.01 M acetic acid, and lyophilized (prolamin fraction). The remaining precipitate was extracted with 2-propanol / water (50 / 50, v / v) / 0.1 mol / L Tris-HCl, pH 7.5, containing 2 mol / L (w / v) urea and 0.06 mol / L (w / v) dithiothreitol (DTT) at 60°C for 30 min. After centrifugation, the supernatant was collected and acetone was added to a final concentration of 40% (V / V). The mixture was left at room temperature for 10 minutes and then centrifuged to precipitate the high molecular weight glutenin (HMW) fraction.

[0361] Purification of recombinant HMW from E. coli for T cell assays

[0362] The bacterial pellet expressing HMW proteins was resuspended in Buffer A (50 mM Tris pH 9, 50 mM NaCl), and the cells were lysed using sonication. The cell lysate was centrifuged, and the pellet was washed with Buffer A. The pellet was solubilized with extraction buffer (8 M urea, 10 mM DTT, 100 mM acetic acid) and incubated at 65°C for 1 hour with vortexing every 10 minutes. The sample was centrifuged, and the supernatant was transferred to a new bottle. DDW was added to the supernatant in a 1:1 ratio and incubated at room temperature for 15 minutes. The sample was centrifuged, and the supernatant was transferred to a new bottle. Acetone was added to 80% and incubated at 4°C for 18 hours. Approximately 80% of the supernatant was discarded, and the remaining volume was centrifuged to form a pellet containing the HMW proteins.

[0363] Pepsin-chemotrypsin digestion of HMW for T cell assays

[0364] 200 mg of protein was first incubated with 4 mg of pepsin in 5% formic acid at 37°C for 4 hours. The sample was then evaporated using a speedvac. The next day, the protein was incubated with 4 mg of chymotrypsin in 20 mM ammonium bicarbonate at 37°C for 4 hours, followed by speedvac evaporation. The concentration of the digest was then measured, and the digest was deamidated using 2 U of transglutaminase per 7 mg of digest for 6 hours at 37°C. The sample was then clarified using a C18 column, dried, and resuspended in medium at a concentration of 2 mg / ml.

[0365] Biopsy processing for T cell line generation

[0366] Gluten-reactive T cell lines (TCLs) were generated based on a previously described method with modifications (Gianfrani, Carmen et al., "Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease." Gastroenterology 133.3 (2007): 780-789). Briefly, mucosal explants were digested with collagenase A and cultured at 2-3 × 10 cells / ml in complete medium X-Vivo 15 (Lonza) supplemented with 5% AB pooled human serum (Biotag) and antibiotics. 5 Cells were seeded at 1.5 × 10 cells / ml. 6 Cells were stimulated with irradiated PBMCs and TG2 (Sigma-Aldrich)-treated (deamidated) pepsin-chemotrypsin (PCT-) digested HMW (50 μg / ml). IL-15 and IL-2 (Peprotech) were added at 10 ng / ml and 20 units / ml, respectively, 24 hours later. Cytokines were replenished every 3–4 days, and cells were split as needed. Cells were restimulated approximately 2 weeks after the initial stimulation.

[0367] T cell activation assay

[0368] T cells derived from biopsies of celiac disease patients were assayed for responses to deamidated PCT-HMW proteins and HMW peptides by enzyme-linked immunosorbent assay (ELISA) detection of IFN-γ, as previously described (Gianfrani, Carmen et al., "Gliadin-specific type 1 regulatory T cells from the intestinal mucosa of treated celiac patients inhibit pathogenic T cells." The Journal of Immunology 177.6 (2006):4178-4186). HLA-matched B-LCL (Sigma-Aldrich) or orthologous PBMCs were used as antigen-presenting cells (APCs). PCT-HMW proteins (100 μg / ml) or peptides (10 μM) (A&A Labs) were incubated with APCs (1 × 10 5 ) was added. (4×10 4Cells were seeded in 200 μl of X-vivo15 medium in round-bottom 96-well plates (Corning) and incubated for 48 hours. Each peptide / protein was tested in quadruplicate. DMSO served as a negative control for peptide testing, and blank medium served as a negative control for protein testing. For ELISA experiments, Nunc MaxiSorp plates (Thermo Fisher) were coated with 1 μg / ml α-IFNγ antibody (Mabtech), blocked, and incubated overnight with 50 μl of sups collected from TCL plates. Recombinant IFNγ (Bactlab) was used for generating a standard curve. Plates were incubated with biotin-α-IFNγ antibody (1 μg / ml) (Mabtech), streptavidin-HRP (Bactlab) (1:5000), and TMB (Thermo Fisher). The reaction was stopped, and the plates were read at 450 nM in an ELISA plate reader. Results were analyzed using Graphpad Prism to determine IFNγ levels. Results were normalized to the control. Results were considered positive (activated T cells) if IFNγ levels were 2-fold or higher in peptide / protein samples compared to the control and if IFNγ levels were significantly higher than the control (one-tailed Student's t-test).

[0369] The results are shown in Figures 3 to 9.

[0370] Figure 3 shows that modifications to the HMW-GS immunogenic peptide (the modified peptides are SEQ ID NOS: 51 and 53) result in abolishment of T cell activation. The mean responses of TCLs from one CD patient biopsy to the tested HMW-GS wild-type and modified peptides were assayed by ELISA to detect IFN-γ levels. Data are presented as the mean ± SD of four experiments performed for each sample. TCL responses to HMW-GS were considered positive if normalized IFN-γ production was significantly higher for the test peptide compared to the control (as determined by one-tailed Student's T-test). * p-val<0.05; ** p<0.01; *** p<0.001).

[0371] Figure 4 shows that modifications to the HMW-GS immunogenic peptide (the modified peptides are SEQ ID NOS: 52, 54, and 55) result in abolishment of T cell activation. The mean responses of TCLs from 16 patient biopsies to the tested HMW-GS wild-type and modified peptides were assayed by ELISA to detect levels of IFN-γ. Data are presented as the mean ± SD of four experiments performed for each sample. TCL responses to HMW-GS were considered positive if normalized IFN-γ production was significantly higher for the test peptide compared to the control (as determined by one-tailed Student's T-test). * p-val<0.05; ** p<0.01; *** p<0.001).

[0372] Figure 5 shows that modifications to the HMW-GS immunogenic peptide (the modified peptide is SEQ ID NO: 56) result in abolishment of T cell activation. The mean responses of TCLs from one CD patient biopsy to the tested HMW-GS wild-type and modified peptides were assayed by ELISA to detect levels of IFN-γ. Data are presented as the mean ± SD of four experiments performed for each sample. TCL responses to HMW-GS were considered positive if normalized IFN-γ production was significantly higher for the test peptide compared to the control (as determined by one-tailed Student's T-test). * p-val<0.05; ** p<0.01; *** p<0.001).

[0373] Figure 6 shows that modifications to the HMW-GS immunogenic peptide (the modified peptide is SEQ ID NO: 143) result in abolishment of T cell activation. The mean responses of TCLs from one CD patient biopsy to the tested HMW-GS WT and modified peptides were assayed by ELISA to detect levels of IFN-γ. Data are presented as the mean ± SD of four experiments performed for each sample. TCL responses to HMW-GS were considered positive if normalized IFN-γ production was significantly higher for the test peptide compared to the control (as determined by one-tailed Student's T-test). * p-val<0.05; ** p<0.01; *** p<0.001).

[0374] Figure 7 shows that modifications to the HMW-GS immunogenic peptide (the modified peptide is SEQ ID NO: 146) result in abolishment of T cell activation. The mean responses of TCLs from one CD patient biopsy to the tested HMW-GS WT and modified peptides were assayed by ELISA to detect levels of IFN-γ. Data are shown as the mean ± SD of four experiments performed for each sample. TCL responses to HMW-GS were considered positive if normalized IFN-γ production was significantly higher for the test peptide compared to the control (as determined by one-tailed Student's T-test). * p-val<0.05; ** p<0.01; *** p<0.001)

[0375] Figure 8 shows that modifications to the HMW-GS immunogenic peptide (the modified peptide is SEQ ID NO: 147) result in abolishment of T cell activation. The mean responses of TCLs from eight patient biopsies to the tested HMW-GS WT and modified peptides were assayed by ELISA to detect levels of IFN-γ. Data are presented as the mean ± SD of four experiments performed for each sample. TCL responses to HMW-GS were considered positive if normalized IFN-γ production was significantly higher for the test peptide compared to the control (as determined by one-tailed Student's T-test). * p-val<0.05; ** p<0.01; *** p<0.001).

[0376] Figure 9 shows that modifications to HMW-GS immunogenic peptides (the modified peptides are SEQ ID NOS: 174, 169, 145, 144, and 176) result in abolishment of T cell activation. The mean responses of TCLs from 16 patient biopsies to the tested HMW-GS WT and modified peptides were assayed by ELISA to detect levels of IFN-γ. Data are presented as the mean ± SD of four experiments performed for each sample. TCL responses to HMW-GS were considered positive if normalized IFN-γ production was significantly higher for the test peptide compared to the control (as determined by one-tailed Student's T-test). * p-val<0.05; ** p<0.01; *** p<0.001)

[0377] Summary: The results demonstrate that modification of the tested glutenin peptide epitopes results in decreased T cell activation (reduced immunogenicity) compared to native and deamidated native peptides.

[0378] Example 3: Evaluation of specific IgE from sera of wheat-allergic patients to wheat extracts and wild-type (WT) and depitope-depleted (DE) HMW glutenin recombinant proteins Objective: To evaluate the allergenicity of recombinant HMW glutenin proteins (wild type - WT and de-epitope variant - DE).

[0379] method:

[0380] Protein purification

[0381] Recombinant bacteria were used to express HMW glutenin WT and variant proteins for purification. HMW glutenin WT Dx5 (SEQ ID NO: 47) and representative depitopened HMW glutenin variants (SEQ ID NOs: 102, 128) were purified by the following procedure: bacterial cell pellets expressing HMW glutenin proteins were resuspended in a lysis buffer containing sucrose, Tris, MgCl, and lysozyme. Cells were lysed using a pressure homogenizer, followed by the addition of DNAse and EDTA. The cell lysate was centrifuged, and the pellet was washed with a wash buffer containing Tris and Tween 20 and centrifuged. The pellet was washed again with 0.1 mM acetate buffer and centrifuged to collect the pellet containing the HMW proteins.

[0382] HMW glutenin WT Dy10 (SEQ ID NO: 48) and a representative de-epitopeed Dy10 (SEQ ID NO: 169) variant protein were produced using the same procedure as described in Example 2 (Purification of recombinant HMW from E. coli for T cell assays).

[0383] Standard ELISA Protocol

[0384] For 384-well ELISA plate coating with antigens, wheat extract (WE), recombinant HMW glutenin (rHMW) Dx5 WT protein (SEQ ID NO: 47), de-epitope (DE) rHMW glutenin Dx5 variants (SEQ ID NOs: 102, 128), rHMW Dy10 WT glutenin protein (SEQ ID NO: 48), and rHMW DE Dy10 glutenin variant (SEQ ID NO: 169) were all solubilized in 8 M urea + 10 mM DTT and diluted 1:200 in carbonate-bicarbonate coating buffer. For BSA-coated wells, blocking buffer (PBS + 0.5% BSA) was used for coating. Each coating antigen was coated in triplicate for each test sample. The plate was incubated overnight at 4°C on an orbital shaker at 120 rpm. The coating solution was discarded, and the wells were blocked with blocking buffer for 1 hour at room temperature on an orbital shaker at 120 rpm. Samples (patient serum and plasma), including a negative control (serum from an individual not allergic to wheat), were diluted 1:12 in dilution buffer (PBST + 0.5% BSA). Anti-HMW glutenin mouse pAb was diluted 1:1000 in dilution buffer. The blocking buffer was discarded, and the diluted samples were added to the wells and incubated overnight at 4°C on an orbital shaker at 120 rpm. The serum was discarded, the plate was washed with PBST, and secondary Ab was added (anti-mouse IgG-HRP for mouse anti-HMW glutenin pAb wells or anti-human IgE-HRP for other samples, diluted 1:10000 in dilution buffer). The plate was incubated for 30 minutes at room temperature on an orbital shaker at 120 rpm, the HRP-conjugated Ab solution was discarded, and the plate was washed with PBST. Signal was developed using TMB substrate.

[0385] For data analysis, the mean values ​​of each triplicate were calculated. For each sample mean, the [(SN) / N] value was determined as follows: S - tested mean, N - negative control mean. For each sample, the [(SN) / N] values ​​for all antigens were plotted and one-way anova was used to determine significance compared to WE: [Table 5]

[0386] result:

[0387] WT Dy10 demonstrates overall similar binding to wheat allergic IgE sera compared to wheat extract, while the DE variants show significantly reduced IgE binding (Figure 10A). WT Dx5 and the DE variants demonstrate statistically lower binding to wheat allergic IgE sera compared to wheat extract (Figure 10B).

[0388] Analysis of the WT and DE variants in an ex vivo assay examining basophil degranulation in response to the WT and modified DE proteins identifies WT or DE variants with reduced allergenicity. A reduced response compared to the response to wheat extract correlates with the WT or DE variant having reduced allergenicity.

[0389] summary:

[0390] Foods that are gliadin-free and have potentially reduced allergenicity of HMW glutenin (recombinant WT or recombinant DE) may be useful for human subjects who suffer from a non-severe allergy to HMW glutenin.

[0391] While certain features of the de-epitope-depleted high molecular weight (HMW) glutenin polypeptides, and methods for making and using the same, have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those skilled in the art. It should therefore be understood that the appended claims are intended to cover all modifications and variations that fall within the true spirit of the de-epitope-depleted high molecular weight (HMW) glutenin polypeptides. [Sequence List Free Text]

[0392] Sequence Listing 1 <223> WT repeat antigenic unit amino acid sequence Sequence Listings 2-33 <223> Repeat antigenic unit amino acid sequence variants Sequence Listing 34 <223> DQ8 alpha chain; GenBank accession number MK501646.1 Sequence Listing 35 <223> Repeat antigenic unit amino acid sequence variants Sequence Listing 36 <223> Writing artificial sequences: synthetic peptides Sequence Listing 36 <223> Meganuclease family recognition sequences Sequence Listings 37-42 <223> Writing artificial sequences: synthetic peptides Sequence Listings 37-42 <223> Repeating antigenic unit amino acid sequence Sequence Listing 49 <223> WT repeat antigenic unit amino acid sequence Sequence Listing 50 <223> Deamidated WT repeat antigenic unit amino acid sequence Sequence Listings 51-56 <223> Writing artificial sequences: synthetic peptides Sequence Listings 51-56 <223> Repeating antigenic unit amino acid sequence Sequence Listing 57-69 <223> Repeat antigenic unit amino acid sequence variants Sequence Listing 70 <223> Writing artificial sequences: synthetic peptides Sequence Listing 70 <223> Meganuclease family recognition sequences Sequence List 71-99 <223> Repeat antigenic unit amino acid sequence variants Sequence Table 100-101 <223> Repeated motifs Sequence Listing 102 <223> Description of artificial sequences: synthetic polypeptides Sequence Listing 102 <223> HMW Dx5 sequence with deleted epitopes and their variations Sequence Listing 103 <223> Description of artificial sequences: synthetic polypeptides Sequence Listing 103 <223> HMW Dy10 sequence with deleted epitopes and their variations Sequence Listing 104 <223> Description of artificial sequences: synthetic polypeptides Sequence Listing 104 <223> HMW Bx7 with deletion Sequence Listing 105 <223> Description of artificial sequences: synthetic polypeptides Sequence Listing 105 <223> HMW By8 with deletion Sequence Listing 106 <223> Description of artificial sequences: synthetic polypeptides Sequence Listing 106 <223> HMW Bx17 with deletion Sequence Listing 107 <223> Description of artificial sequences: synthetic polypeptides Sequence Listing 107 <223> HMW By18 with deletion Sequence list 108-125 <223> Writing artificial sequences: synthetic peptides Sequence list 108-125 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence list 126-129 <223> Description of artificial sequences: synthetic polypeptides Sequence list 126-129 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence Listing 130 <223> Description of artificial sequences: synthetic polypeptides Sequence Listing 130 <223> Depitope-depleted high molecular weight glutenin partial sequence (BP254) Sequence list 131-138 <223> Description of artificial sequences: synthetic polypeptides Sequence list 131-138 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence Listing 139 <223> DQ8 beta chain; GenBank accession number OU241996.1 Sequence Table 140-142 <223> Description of artificial sequences: synthetic polypeptides Sequence Table 140-142 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence Table 143-144 <223> Writing artificial sequences: synthetic peptides Sequence Table 143-144 <223> Engineered peptide chains Sequence Listing 145 <223> Writing artificial sequences: synthetic peptides Sequence Listing 145 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence Table 146-147 <223> Writing artificial sequences: synthetic peptides Sequence Table 146-147 <223> Engineered peptide chains Sequence list 148~151 <223> Description of artificial sequences: synthetic polypeptides Sequence list 148~151 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence list 155~168 <223> Description of artificial sequences: synthetic polypeptides Sequence list 155~168 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence Listing 169 <223> Writing artificial sequences: synthetic peptides Sequence Listing 169 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence list 170-172 <223> Description of artificial sequences: synthetic polypeptides Sequence list 170-172 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence list 173-179 <223> Writing artificial sequences: synthetic peptides Sequence list 173-179 <223> Depitope-depleted high molecular weight glutenin partial sequence Sequence Listing 180 <223> Repeated motifs

Claims

1. A de-epitope-modified HMW glutenin (HMW), comprising: Contains repeating antigenic units, At least one of the repeating antigenic units comprises a first mutation at position 1 of the repeating antigenic unit and a second mutation at position 9 of the repeating antigenic unit; The amino acid sequence of the non-mutated antigenic repeat unit is any of the sequences set forth in SEQ ID NOs: 1-33, 35, or 71-99; The first mutation and the second mutation each include an amino acid substitution mutation or an amino acid deletion.

2. (a) the first mutation at position 1 of the antigenic unit is a substitution with a histidine and the second mutation at position 9 of the antigenic unit is a substitution with a histidine; (b) the first mutation at position 1 of the antigenic unit is a substitution with a proline and the second mutation at position 9 of the antigenic unit is a substitution with an arginine; (c) the first mutation at position 1 of the antigenic unit is a substitution with alanine and the second mutation at position 9 of the antigenic unit is a substitution with arginine; (d) the first mutation at position 1 of the antigenic unit is a substitution with serine and the second mutation at position 9 of the antigenic unit is a substitution with threonine; (e) the first mutation at position 1 of the antigenic unit is a substitution with glutamic acid and the second mutation at position 9 of the antigenic unit is a substitution with glutamic acid; (f) said first mutation at position 1 of the antigenic unit is a substitution with a proline and the substitution at position 9 of the antigenic unit is a substitution with a threonine; (g) the first mutation at position 1 of the antigenic unit is a substitution with glutamic acid and the second mutation at position 9 of the antigenic unit is a substitution with lysine or arginine; or (h) the first mutation at position 1 of the antigenic unit is a substitution with glutamic acid or lysine and the second mutation at position 9 of the antigenic unit is a substitution with histidine; or (i) the first mutation or the second mutation, or both, comprise a deletion of amino acids at positions 1 to 9 of the repeat antigenic unit; (j) any combination of (a) to (i) when two or more repeating antigenic units are mutated; The depitope-modified HMW glutenin of claim 1.

3. A de-epitope-modified HMW glutenin as described in claim 1 or 2, comprising at least two additional substitution mutations at either position 3, 5, or 8 of at least one repeating antigenic unit.

4. 4. The depitope-modified HMW glutenin of claim 3, wherein the substitution at position 5 is leucine and the substitution at position 3 is arginine.

5. The de-epitope-modified HMW glutenin of claim 1 or claim 2, comprising an amino acid sequence set forth in any one of SEQ ID NOs: 52, 102-107, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, 155-168, or 170-172.

6. An isolated polynucleotide encoding the epitope-depleted HMW glutenin according to any one of claims 1 to 5.

7. 7. An expression vector comprising the isolated polynucleotide of claim 6 operably linked to a transcriptional regulatory sequence so as to enable expression of the depitope-substituted high molecular weight glutenin in a cell.

8. 1. A method for producing depitope-modified HMW glutenin, comprising: (a) culturing a cell comprising the expression vector of claim 7 under conditions that allow expression of the depitope-modified HMW glutenin in the cell; (b) expressing the depitope-modified HMW glutenin; and (c) recovering the expressed depitoplated HMW glutenin. The method includes:

9. A cell comprising the epitope-depleted HMW glutenin according to any one of claims 1 to 5.

10. A method for depitopylating HMW glutenin containing repeating antigenic units, comprising: Mutating the amino acid residues at positions 1 and 9 of at least one repeating antigenic unit of said HMW glutenin, The non-mutated repeat antigenic unit has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 33, 35, or 71 to 99, The mutations at positions 1 and 9 each include an amino acid substitution mutation or an amino acid deletion.

11. The method according to claim 10, wherein the substitution mutation at position 9 of the repeating antigenic unit comprises a substitution in: (a) a positively charged amino acid selected from arginine, histidine, or lysine; (b) a small amino acid selected from serine or threonine; (c) glutamic acid; or (d) Combinations where two or more repeating antigenic units are mutated.

12. (a) the substitution at position 1 of the antigenic unit is a substitution with histidine and the substitution at position 9 of the antigenic unit is a substitution with histidine; or (b) the substitution at position 1 of the antigenic unit is a substitution with proline and the substitution at position 9 of the antigenic unit is a substitution with arginine; or (c) the substitution at position 1 of the antigenic unit is a substitution with alanine and the substitution at position 9 of the antigenic unit is a substitution with arginine; or (d) the substitution at position 1 of the antigenic unit is a substitution with serine and the substitution at position 9 of the antigenic unit is a substitution with threonine; or (e) the substitution at position 1 of the antigenic unit is a substitution with glutamic acid and the substitution at position 9 of the antigenic unit is a substitution with glutamic acid; or (f) the substitution at position 1 of the antigenic unit is a substitution with proline and the substitution at position 9 of the antigenic unit is a substitution with threonine; or (g) the substitution at position 1 of the antigenic unit is a substitution with glutamic acid and the substitution at position 9 of the antigenic unit is a substitution with lysine or arginine; or (h) the substitution at position 1 of the antigenic unit is a substitution with glutamic acid or lysine and the substitution at position 9 of the antigenic unit is a substitution with histidine; or (i) any combination of (a) to (h) when two or more repeating antigenic units are mutated; 12. The method according to claim 10 or 11.

13. The method according to any of claims 10 to 12, further comprising mutating at least two amino acids at positions 3, 5 or 8 of the repeating antigenic unit.

14. 14. The method of claim 13, wherein the mutation at position 5 is a substitution of the amino acid with leucine and the mutation at position 3 is a substitution of the amino acid with arginine.

15. The method of claim 10, further comprising deleting amino acids 1 to 9 of the repeating antigenic unit.

16. 16. The method of any of claims 10-15, wherein the depitope-modified HMW glutenin comprises an amino acid sequence set forth in any of SEQ ID NOs: 52, 102-107, 109-112, 114-116, 118-119, 126-134, 137-138, 140-142, 148-151, 155-168, or 170-172.

17. Flour comprising the epitope-depleted HMW glutenin according to any one of claims 1 to 5.

18. A modified wheat expressing the epitope-depleted HMW glutenin according to any one of claims 1 to 5.

19. A modified corn plant expressing the epitope-depleted HMW glutenin of any one of claims 1 to 5.

20. Flour derived from the wheat of claim 18.

21. A dough comprising the flour according to claim 17 or claim 20.